WO2020150032A1 - Compositions topiques comprenant un néonicotinoïde et une lactone macrocyclique, procédés et utilisations associés - Google Patents

Compositions topiques comprenant un néonicotinoïde et une lactone macrocyclique, procédés et utilisations associés Download PDF

Info

Publication number
WO2020150032A1
WO2020150032A1 PCT/US2020/012450 US2020012450W WO2020150032A1 WO 2020150032 A1 WO2020150032 A1 WO 2020150032A1 US 2020012450 W US2020012450 W US 2020012450W WO 2020150032 A1 WO2020150032 A1 WO 2020150032A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrrolidone
pharmaceutically acceptable
imidacloprid
abamectin
combination
Prior art date
Application number
PCT/US2020/012450
Other languages
English (en)
Inventor
Alan Leslie JOHNSON
Amit Kumar Jain
Original Assignee
Boehringer Ingelheim Animal Health USA Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Animal Health USA Inc. filed Critical Boehringer Ingelheim Animal Health USA Inc.
Priority to AU2020208145A priority Critical patent/AU2020208145B2/en
Priority to NZ776819A priority patent/NZ776819A/en
Publication of WO2020150032A1 publication Critical patent/WO2020150032A1/fr
Priority to AU2023200609A priority patent/AU2023200609A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N51/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds having the sequences of atoms O—N—S, X—O—S, N—N—S, O—N—N or O-halogen, regardless of the number of bonds each atom has and with no atom of these sequences forming part of a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention provides topical veterinary compositions comprising at least one neonicotinoid active agent and at least one macrocyclic lactone active agent for controlling ectoparasites and endoparasites in and on animals.
  • the invention also provides for the use of these compositions against ectoparasites and/or endoparasites, and methods for preventing or treating parasitic infections and infestations in animals using the compositions.
  • ectoparasites such as insects
  • endoparasites such as filariae and other worms
  • domesticated animals such as cats and dogs, are often infested with one or more of the following ectoparasites:
  • - fleas e.g. Ctenocephalides spp., such as Ctenocephalides felis and the like
  • - ticks e.g. Rhipicephalus spp., Ixodes spp., Dermacentor spp., Amblyomma spp., and the like
  • - mites e.g. Demodex spp., Sarcoptes spp., Otodectes spp., and the like
  • - lice e.g. Trichodectes spp., Cheyletiella spp., Linognathus spp. and the like
  • - mosquitoes edes spp., Culex spp., Anopheles spp. and the like
  • Fleas are a particular problem because not only do they adversely affect the health of the animal or human, but they also cause a great deal of psychological stress. Moreover, fleas are also vectors of pathogenic agents in animals and humans, such as dog tapeworm (Dipylidium caninum). Similarly, ticks are also harmful to the physical and psychological health of the animal or human. However, the most serious problem associated with ticks is that they are the vector of pathogenic agents in both humans and animals.
  • ticks Major diseases which are caused by ticks include borreliosis (Lyme disease caused by Borrelia burgdorferi), babesiosis (or piroplasmosis caused by Babesia spp.) and rickettsioses (also known as Rocky Mountain spotted fever). Ticks also release toxins which cause inflammation or paralysis in the host. Occasionally, these toxins are fatal to the host.
  • farm animals are also susceptible to parasite infestations.
  • cattle and sheep are affected by a large number of parasites.
  • Parasites that are particularly harmful against sheep include body lice (Bovicola ovis) and gastrointestinal nematodes including, but not limited to, Haemonchus contortus, Telodorsagia circumcinta and Trichostrongylus colubriformis.
  • Sheep body lice are ubiquitous parasites of sheep and are estimated to cost Australian sheep producers $120 million per year in costs of control, loss of production and fleece derangement.
  • Sheep lice may also become a significant welfare problem due to the discomfort caused to sheep while fleece derangement makes them more susceptible to other serious conditions such as flystrike.
  • Sheep roundworms are a ubiquitous parasite of sheep resulting in increased costs of control and loss of production. Roundworms are also a significant welfare problem due to potential mortality and scouring causing predisposition to flystrike.
  • a parasite which is very prevalent among farm animals is the tick genus Rhipicephalus, especially those of the species microplus (cattle tick), decoloratus and annulatus. Ticks, such as Boophilus microplus, are particularly difficult to control because they live in the pasture where farm animals graze.
  • helminthiasis which is most frequently caused by a group of parasitic worms categorized as cestodes (tapeworm), nematodes (roundworm) and trematodes (flatworm or flukes). These parasites adversely affect the nutrition of the animal and cause severe economic losses in pigs, sheep, horses, and cattle as well as affecting domestic animals and poultry.
  • parasites which occur in the gastrointestinal tract of animals and humans include Ancylostoma, Necator, Ascaris, Strongyloides, Trichinella, Capillaria, Toxocara, Toxascaris, Trichuris, Enterobius and parasites which are found in the blood or other tissues and organs such as filarial worms and the extra intestinal stages of Strongyloides, Toxocara and Trichinella
  • Milbemycin or avermectin compounds are natural or semi-synthetic compounds that contain a 16-membered macrocyclic ring.
  • the avermectin and milbemycin series of compounds are potent anthelmintic and antiparasitic agents against a wide range of internal and external parasites.
  • the natural product avermectins are disclosed in U.S. Patent 4,310,519 to Albers-Schonberg, et al., and the 22, 23-dihydro-avermectin compounds are disclosed in Chabala, et al., U.S. Patent 4,199,569.
  • avermectins which include a discussion of their uses in humans and animals, see“Ivermectin and Abamectin,” W.C. Campbell, ed., Springer-Verlag, New York (1989).
  • Naturally occurring milbemycins are described in Aoki et al., U.S. Patent No.3,950,360.
  • Abamectin is a naturally-occurring compound of the avermectin family and consists of a mixture of isomeric compounds, isomer B1a and isomer B1b, which differ by a single methylene group.
  • the B 1a and B 1b isomers have the following structures:
  • Abamectin has been approved for use in animal medicine and is the starting material for the semi-synthetic avermectin, ivermectin. Abamectin differs from ivermectin only in the presence of a double bond at C-22/C-23. Abamectin exhibits superb potency against most species of gastrointestinal nematodes via subcutaneous injection.
  • Abamectin like other avermectins, binds selectively and with high affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the parasite.
  • the neonicotinoids are a class of ectoparasiticides that bind and inhibit insect specific nicotinic acetylcholine receptors.
  • the topical formulation of the invention will comprise at least one neonicotinoid insecticidal agent combined with at least one macrocyclic lactone active agent.
  • Imidacloprid is a well-known neonicotinoid active agent and is the key active ingredient in the topical parasiticide products Advantage ® , Advantage ® II, K9 Advantix ® , and K9 Advantix ® II sold by Bayer Animal Health. Agents of this class are described, for example, in U.S. Patent No.
  • Nitenpyram is the active ingredient in the oral product CAPSTARTM Tablets sold by Novartis Animal Health. Nitenpyram has a very fast onset of action against fleas. For example, CAPSTARTM Tablets begin to act against fleas in as early as 30 minutes after administration and is indicated for use as often as once a day.
  • Imidacloprid is also used as a lousicide for sheep sold as the product AVENGETM by Bayer Australia Ltd. However, since imidacloprid is not active against internal nematodes, products containing imidacloprid only are not effective against internal parasites.
  • AVENGETM contains 3.5% (w/v) imidacloprid in a carrier comprising 30% (w/v) N-methylpyrrolidone and > 60% (w/v) dipropylene glycol monomethyl ether.
  • compositions comprising a milbemycin or avermectin active agent alone or in combination with other active agents described in the documents above, there is a need for veterinary compositions and methods with improved efficacy and spectrum of coverage and increased shelf life to protect animals against both endoparasites and ectoparasites.
  • the present invention provides topical compositions comprising at least one macrocyclic lactone compound in combination with at least one neonicotinoid compound; uses thereof for the treatment or prophylaxis of parasitic infections and infestations of animals (either wild or domesticated), including livestock and companion animals such as cats, dogs, horses, chickens, sheep, goats, pigs, turkeys and cattle.
  • the topical veterinary composition of the invention are advantageously in the form of a spot-on or a pour-on formulation for application to localized areas on the animal to be treated.
  • the topical compositions of the invention comprise a macrocyclic lactone active agent selected from the group consisting of abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin and selamectin; and milbemycins such as milbemectin, milbemycin D, milbemycin oxime, moxidectin and nemadectin. Also included are the 5-oxo and 5-oxime derivatives of said avermectins and milbemycins.
  • the neonicotinoid active agent is acetamiprid, clothianidin, dinotofuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam, or a mixture thereof. In a preferred embodiment, the neonicotinoid active agent is imidacloprid.
  • the invention also provides methods for the treatment or prevention of parasitic infections and infestations in animals, comprising administering an effective amount of a composition described herein to the animal.
  • the present invention provides also provides uses of the compositions described for the treatment or prevention of a parasitic infestation or infection in an animal.
  • the present invention provides surprisingly stable and efficacious compositions comprising at least one macrocyclic lactone compound in combination with at least one neonicotinoid compound together with a pharmaceutically acceptable carrier or diluent, and optionally an antioxidant.
  • the invention provides topical compositions that comprise an effective amount of at least one macrocyclic lactone active agent in combination with an effective amount of at least one neonicotinoid active agent, or pharmaceutically acceptable salts, hydrates or solvates thereof; together with a pharmaceutically acceptable carrier that comprises a combination of a pyrrolidone solvent and a glycol ether solvent, and optionally an antioxidant.
  • the invention provides topical compositions that comprise at an effective amount of an avermectin or milbemycin active agent in combination with an effective amount of at least one neonicotinoid active agent, or pharmaceutically acceptable salts, hydrates or solvates thereof; together with a pharmaceutically acceptable carrier that comprises a combination of a pyrrolidone solvent and a glycol ether solvent, and optionally an antioxidant.
  • the compositions are in a form that is suitable for topical administration.
  • the composition is a spot-on formulation that is applied to a localized area on an animal.
  • the compositions of the invention are in the form of pour-on formulations.
  • Pour-on formulations typically differ from spot-on formulations in that they are higher volume formulations that are applied as a stripe down the back side of the animal, e.g. a stripe from head to tail of the animal.
  • Pour-on formulations are typically used with livestock animals such as sheep and cattle while spot-on formulations are typically used with companion animals such as cats and dogs. These formulations provide surprisingly effective protection of the animals against ectoparasites and endoparasites for an extended period of time.
  • the compositions of the invention comprise at least one avermectin or milbemycin compound.
  • the at least one avermectin or milbemycin compound is abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, moxidectin or nemadectin.
  • the compositions of the invention comprise abamectin.
  • compositions of the invention comprise acetamiprid, clothianidin, dinotofuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam, or a mixture thereof.
  • the neonicotinoid active agent in the topical compositions is imidacloprid.
  • the compounds of the invention are intended to include all stereoisomers and crystalline forms (which includes hydrated forms, polymorphic forms and amorphous forms with up to 15% by weight crystalline structure) thereof.
  • animal is used herein to include all mammals, birds and fish and also include all vertebrate animals, including humans.
  • Animals include, but are not limited to, humans, cats, dogs, cattle, chickens, cows, deer, goats, horses, llamas, pigs, sheep and yaks. It also includes an individual animal in all stages of development, including embryonic and fetal stages.
  • an effective amount of a composition of the invention is intended a sufficient amount of a composition of the invention to eradicate or reduce the number of parasites infesting the animal.
  • an effective amount of the active agent achieves at least 70% efficacy against the target parasite.
  • an effective amount of the active agent achieves at least 80%, or at least 90% efficacy against the target pests.
  • an effective amount of the active agent will achieve at least 95%, at least 98% or 100% efficacy against the target parasites.
  • compositions of the invention may exist and be isolated as optically active and racemic forms.
  • Compounds having one or more chiral centers, including at a sulfur atom may be present as single enantiomers or diastereomers or as mixtures of enantiomers and/or diastereomers.
  • sulfoxide compounds may be optically active and may exist as single enantiomers or racemic mixtures.
  • compounds within the compositions of the invention may include one or more chiral centers, which results in a theoretical number of optically active isomers.
  • the compounds may comprise up to 2 n optical isomers.
  • the present invention encompasses the specific enantiomers or diastereomers of each compound as well as mixtures of different enantiomers and/or diastereomers of the compounds of the invention that possess the useful properties described herein.
  • the optically active forms can be prepared by, for example, resolution of the racemic forms by selective crystallization techniques, by synthesis from optically active precursors, by chiral synthesis, by chromatographic separation using a chiral stationary phase or by enzymatic resolution.
  • compositions of present invention may also be present in different solid forms such as different crystalline forms or in the form of an amorphous solid.
  • present invention encompasses different crystalline forms as well as amorphous forms of the inventive compounds.
  • compositions of the invention may exist as hydrates or solvates, in which a certain stoichiometric amount of water or a solvent is associated with the molecule in the crystalline form.
  • the compositions of the invention may include hydrates and solvates of the active agents.
  • the term "acid” contemplates all pharmaceutically acceptable inorganic or organic acids.
  • Inorganic acids include mineral acids such as hydrohalic acids such as hydrobromic acid and hydrochloric acid, sulfuric acid, phosphoric acids and nitric acid.
  • Organic acids include all pharmaceutically acceptable aliphatic, alicyclic and aromatic carboxylic acids, dicarboxylic acids, tricarboxylic acids and fatty acids.
  • the acids are straight chain or branched, saturated or unsaturated C1-C20 aliphatic carboxylic acids, which are optionally substituted by halogen or by hydroxyl groups, or C 6 -C 12 aromatic carboxylic acids.
  • acids examples include carbonic acid, formic acid, acetic acid, propionic acid, isopropionic acid, valeric acid, D-hydroxy acids such as glycolic acid and lactic acid, chloroacetic acid, benzoic acid, methane sulfonic acid, and salicylic acid.
  • dicarboxylic acids include oxalic acid, malic acid, succinic acid, tartaric acid, fumaric acid, and maleic acid.
  • An example of a tricarboxylic acid is citric acid.
  • Fatty acids include all pharmaceutically acceptable saturated or unsaturated aliphatic or aromatic carboxylic acids having 4 to 24 carbon atoms.
  • Examples include butyric acid, isobutyric acid, sec-butyric acid, lauric acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, and phenylsteric acid.
  • Other acids include gluconic acid, glucoheptonic acid and lactobionic acid.
  • base contemplates all pharmaceutically acceptable inorganic or organic bases, including hydroxides, carbonates or bicarbonates of alkali metal or alkaline earth metals.
  • Salts formed with such bases include, for example, the alkali metal and alkaline earth metal salts, including, but not limited to, as the lithium, sodium, potassium, magnesium or calcium salts.
  • Salts formed with organic bases include the common hydrocarbon and heterocyclic amine salts, which include, for example, ammonium salts (NH4 + ), alkyl- and dialkylammonium salts, and salts of cyclic amines such as the morpholine and piperidine salts.
  • the invention provides compositions that comprise at least one macrocyclic lactone active agent in combination with at least one neonicotinoid active agent, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier or diluent that comprises a pyrrolidone solvent and a glycol ether solvent, and optionally an antioxidant.
  • the macrocyclic lactone compounds are also well known in the art and can be obtained commercially or through known synthesis techniques.
  • avermectins ivermectin and abamectin
  • Macrocyclic lactones are either natural products or are semi-synthetic derivatives thereof.
  • the structures of the avermectins and milbemycins are closely related, e.g., by sharing a complex 16-membered macrocyclic lactone ring; milbemycins lack the glycosidic moiety of the avermectins.
  • the natural products avermectins are disclosed in U.S. Patent No.4,310,519 to Albers-Schönberg et al., and the 22,23-dihydro avermectin compounds are disclosed in Chabala et al., U.S. Patent No.4,199,569. Mention is also made of Kitano, U.S. Patent No.
  • Latidectin is described in the “International Nonproprietary Names for Pharmaceutical Substances (INN)”, WHO Drug Information, vol.17, no.4, pp.263- 286, (2003).
  • Semisynthetic derivatives of these classes of compounds are well known in the art and are described, for example, in U.S. Patent No. 5,077,308, U.S. Patent No.4,859,657, U.S. Patent No.4,963,582, U.S. Patent No.4,855,317, U.S. Patent No.4,871,719, U.S. Patent No.4,874,749, U.S. Patent No.4,427,663, U.S. Patent No. 4,310,519, U.S. Patent No.
  • the neonicotinoids are a class of ectoparasiticides that bind and inhibit insect specific nicotinic acetylcholine receptors.
  • Imidacloprid is a well-known neonicotinoid active agent and is the key active ingredient in the topical parasiticide products Advantage ® , Advantage ® II, K9 Advantix ® , and K9 Advantix ® II sold by Bayer Animal Health. Agents of this class are described, for example, in U.S. Patent No. 4,742,060 or in EP 0 892 060, (incorporated by reference) among others.
  • Veterinary compositions comprising neonicotinoid active agents are described in U.S. Patent Nos.
  • Nitenpyram is the active ingredient in the oral product CAPSTARTM Tablets sold by Novartis Animal Health.
  • the avermectin and milbemycin active agents include, but are not limited to, abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, moxidectin or nemadectin, or mixtures of these active agents.
  • Neonicotinoid active agents that may be included in the compositions of the invention include, but are not limited to, acetamiprid, clothianidin, dinotofuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam, and combinations thereof.
  • Neonicotinoid active agents that may be included in the compositions of the invention also include newer neonicotinoids such as guadipyr and huanyanglin (see, e.g., N. Simon-Delso et al., (2015) Systemic insecticides (neonicotinoids and fipronil): trends, uses, mode of action and metabolites. Environ Sci Pollut Res 22:5-34; and Shao X, Swenson TL, Casida JE; (2013) Cycloxaprid insecticide: nicotinic acetylcholine receptor binding site and metabolism.
  • J Agric Food Chem 61:7883–7888 and also include neonicotinoid-like insecticides such as cis- neonicotinoids (e.g. cycloxaprid and paichongding, see Shao X, Liu Z, Xu X, Li Z, Qian X (2013) Overall status of neonicotinoid insecticides in China: production, application and innovation. J Pest Sci 38:1–9; and ), nitroguanidine thiazole neonicotinoids (e.g. imidaclothiz, see Wu M, Cai J, Yao J, Dai B, Lu Y (2010) Study of imidaclothiz residues in cabbage and soil by HPLC with UVdetection.
  • neonicotinoid-like insecticides such as cis- neonicotinoids (e.g. cycloxaprid and paichongding, see Shao X, Liu Z, Xu X, Li Z, Qian X (2013)
  • Pyrrolidone solvents that may be used in the compositions of the invention include, but are not limited to, 2-pyrrolidone, 1-(C1-20-alkyl)-2-pyrrolidone, in particular 1- methylpyrrolidone (also known as N-methylpyrrolidone), 1-ethylpyrrolidone, 1-n- propylpyrrolidone, l-octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, l-(s- or t- or n-butyl)pyrrolidone, 1-hexylpyrrolidone, 1-(C 2 - 20 -alkenyl)-2-pyrrolidone such as 1-vinyl- 2-pyrrolidone, 1-(C3-8cycloalkyl)-2-pyrrolidone such as 1-cyclohexylpyrrolidone, 1-(C1-6- hydroxyalkyl)-2-pyrrol
  • Glycol ether solvents that may be used in the compositions of the invention include, but are not limited to, diethylene glycol monoethyl ether (Transcutol ® ), butyl diglycol, propylene glycol monomethyl ether, propylene glycol monoethyl ether, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether and dipropylene glycol monomethyl ether, or a combination thereof.
  • diethylene glycol monoethyl ether Transcutol ®
  • butyl diglycol propylene glycol monomethyl ether
  • propylene glycol monoethyl ether propylene glycol monoethyl ether
  • dipropylene glycol n-butyl ether dipropylene glycol n-butyl ether
  • ethylene glycol monoethyl ether ethylene glycol monomethyl ether
  • dipropylene glycol monomethyl ether
  • the pyrrolidone solvent will typically be present in the compositions of the invention in a concentration of about 10% (w/v) to about 50% (w/v). In one embodiment, the pyrrolidone solvent will be present in a concentration of about 20% to about 50% (w/v). In yet other embodiments, the pyrrolidone solvent will be present in a concentration of about 20% to about 40% (w/v) or about 25% to about 35% (w/v). In a particular embodiment, the compositions of the invention will comprise about 30% (w/v) of a pyrrolidone solvent.
  • the invention provides surprisingly stable topical compositions (e.g., spot-on, pour-on) comprising a combination of macrocyclic lactone active agent in combination with at least one neonicotinoid active agent having an extended shelf-life for the treatment or prevention of a parasitic infection or infestation in an animal, wherein the composition has a shelf-life of at least 6 months, at least 12 months, at least 18 months, at least 24 months, at least 36 months, or at least 48 months.
  • compositions e.g., spot-on, pour-on
  • the composition has a shelf-life of at least 6 months, at least 12 months, at least 18 months, at least 24 months, at least 36 months, or at least 48 months.
  • the invention provides topical compositions that comprise an effective amount of at least one avermectin or milbemycin active agent selected from the group consisting of abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, moxidectin and nemadectin, or a mixture thereof, in combination with an effective amount of at least one neonicotinoid active agent selected from the group consisting of acetamiprid, clothianidin, dinotofuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam, or a combination thereof, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises a combination of
  • the invention provides topical compositions that comprise a combination of an effective amount of abamectin and an effective amount of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises a combination of a pyrrolidone solvent and a glycol ether solvent, and optionally an antioxidant.
  • the invention provides topical compositions that comprise a combination of an effective amount of abamectin and an effective amount of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises a combination of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t- butylpyrrolidone, 1-n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2-pyrrolidone, 1- cyclohexylpyrrolidone, 1-(2-hydroxyethyl)-pyrrolidone, 1-3-hydroxypropyl)pyrrolidon
  • the invention provides topical compositions that comprise a combination of an effective amount of abamectin and an effective amount of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises a combination of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t- butylpyrrolidone, 1-n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2-pyrrolidone, 1- cyclohexylpyrrolidone, 1-(2-hydroxyethyl)-pyrrolidone, 1-3-hydroxypropyl)pyrrolidon
  • the invention provides topical compositions that comprise a combination of an effective amount of abamectin and an effective amount of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises a combination of N-methylpyrrolidone and dipropylene glycol monomethyl ether, and optionally an antioxidant.
  • the invention provides topical compositions that comprise a combination of an effective amount of abamectin and an effective amount of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises a combination of N-methylpyrrolidone and dipropylene glycol monomethyl ether, and butylated hydroxytoluene or butylated hydroxyanisole.
  • the invention provides topical compositions consisting essentially of an effective amount of a macrocyclic lactone active agent, an effective amount of a neonicotinoid active agent, or pharmaceutically acceptable salts, hydrates or solvates thereof, a pyrrolidone solvent, a glycol ether solvent and an antioxidant.
  • the invention provides topical compositions consisting essentially of an effective amount of an avermectin or milbemycin active agent, an effective amount of a neonicotinoid active agent, or pharmaceutically acceptable salts, hydrates or solvates thereof, a pyrrolidone solvent, a glycol ether solvent, and an antioxidant.
  • the invention provides topical compositions consisting essentially of an effective amount of an avermectin or milbemycin active agent selected from the group consisting of abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, moxidectin and nemadectin, an effective amount of a neonicotinoid active agent selected from the group consisting of acetamiprid, clothianidin, dinotofuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam, or a combination thereof, or pharmaceutically acceptable salts, hydrates or solvates thereof, a pyrrolidone solvent, a glycol ether solvent, and an antioxidant.
  • the invention provides topical compositions consisting essentially of an effective amount of abamectin, an effective amount of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, a pyrrolidone solvent, a glycol ether solvent, and an antioxidant.
  • the invention provides topical compositions consisting essentially of an effective amount of abamectin and an effective amount of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l- octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t- butylpyrrolidone, 1-n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2-pyrrolidone, 1- cyclohexylpyrrolidone, 1-(2-hydroxyethyl)-pyrrolidone, 1-3-hydroxypropyl)pyrrolidone, 1- (2-methoxyethyl)-
  • the invention provides topical compositions consisting essentially of an effective amount of abamectin, an effective amount of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l- octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t- butylpyrrolidone, 1-n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2-pyrrolidone, 1- cyclohexylpyrrolidone, 1-(2-hydroxyethyl)-pyrrolidone, 1-3-hydroxypropyl)pyrrolidone, 1- (2-methoxyethyl)-
  • the invention provides topical compositions consisting essentially of an effective amount of abamectin, an effective amount of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, N-methylpyrrolidone, dipropylene glycol monomethyl ether, and butylated hydroxytoluene.
  • the invention provides topical compositions consisting of an effective amount of an avermectin or milbemycin active agent, an effective amount of a neonicotinoid active agent, or pharmaceutically acceptable salts, hydrates or solvates thereof, a pyrrolidone solvent, a glycol ether solvent, an antioxidant and a dye.
  • the invention provides topical compositions consisting of an effective amount of an avermectin or milbemycin active agent selected from the group consisting of abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, moxidectin and nemadectin, an effective amount of a neonicotinoid active agent selected from the group consisting of acetamiprid, clothianidin, dinotofuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam, or a combination thereof, or pharmaceutically acceptable salts, hydrates or solvates thereof, a pyrrolidone solvent, a glycol ether solvent, an antioxidant and a dye.
  • the invention provides topical compositions consisting of an effective amount of abamectin, an effective amount of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, a pyrrolidone solvent, a glycol ether solvent, an antioxidant and a dye.
  • the invention provides topical compositions consisting of an effective amount of abamectin and an effective amount of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1- dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t-butylpyrrolidone, 1- n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2-pyrrolidone, 1-cyclohexylpyrrolidone, 1- (2-hydroxyethyl)-pyrrolidone, 1-3-hydroxypropyl)pyrrolidone, 1-(2-methoxyethyl)- pyrrolidone, 1-
  • the invention provides topical compositions consisting of an effective amount of abamectin, an effective amount of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof; a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1- dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t-butylpyrrolidone, 1- n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2-pyrrolidone, 1-cyclohexylpyrrolidone, 1- (2-hydroxyethyl)-pyrrolidone, 1-3-hydroxypropyl)pyrrolidone, 1-(2-methoxyethyl)- pyrrolidone, 1-
  • the invention provides topical compositions consisting of an effective amount of abamectin, an effective amount of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, N-methylpyrrolidone, dipropylene glycol monomethyl ether, butylated hydroxytoluene and a dye.
  • compositions of the invention will comprise between about 0.1 to about 20% (w/v) of the neonicotinoid active agent.
  • the compositions may comprise about 0.1% to about 10% (w/v), about 0.1% to about 5% (w/v) or about 1% to about 5% (w/v) of the neonicotinoid active agent.
  • the compositions of the invention may comprise about 2% to about 4% of the neonicotinoid active agent.
  • the composition will include about 3.5% (w/v) of the neonicotinoid active agent.
  • compositions of the invention will typically comprise about 0.01% to about 5% of the macrocyclic lactone active agent. In other embodiments, the compositions will comprise about 0.1% to about 5% (w/v) or about 0.1 to about 2% (w/v) of the macrocyclic lactone active agent. In another embodiment, the compositions of the invention will comprise about 0.1% to about 1% (w/v) or about 0.4% (w/v) of the macrocyclic lactone active agent.
  • the invention provides topical compositions that comprise about 0.1% (w/v) to about 5% (w/v) of an avermectin or milbemycin active agent in combination with about 1% (w/v) to about 10% (w/v) of a neonicotinoid active agent, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 10% (w/v) to about 50% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), and optionally an antioxidant.
  • a pharmaceutically acceptable carrier that comprises about 10% (w/v) to about 50% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), and optionally an antioxidant.
  • the invention provides topical compositions that comprise about 0.1% (w/v) to about 5% (w/v) of at least one avermectin or milbemycin active agent selected from the group consisting of abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, moxidectin and nemadectin, or a mixture thereof, in combination with about 1% (w/v) to about 10% (w/v) of at least one neonicotinoid active agent selected from the group consisting of acetamiprid, clothianidin, dinotofuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam, or a combination thereof, or pharmaceutically
  • the invention provides topical compositions that comprise a combination of about 0.1% (w/v) to about 5% (w/v) of abamectin and about 1% (w/v) to about 10% (w/v) imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 10% (w/v) to about 50% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), and optionally an antioxidant.
  • a pharmaceutically acceptable carrier that comprises about 10% (w/v) to about 50% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), and optionally an antioxidant.
  • the invention provides topical compositions that comprise about 0.1% (w/v) to about 5% (w/v) of abamectin and about 1% (w/v) to about 10% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 10% (w/v) to about 50% (w/v) of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec- butylpyrrolidone, 1-t-butylpyrrolidone, 1-n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2- pyrrolidone, 1-cyclohexy
  • the invention provides topical compositions that comprise about 0.1% (w/v) to about 5% (w/v) of abamectin and about 1% (w/v) to about 10% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 10% (w/v) to about 50% (w/v) of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec- butylpyrrolidone, 1-t-butylpyrrolidone, 1-n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2- pyrrolidone, 1-cyclohexy
  • the invention provides topical compositions that comprise about 0.1% (w/v) to about 5% (w/v) of abamectin and about 1% (w/v) to about 10% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 10% (w/v) to about 50% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and optionally an antioxidant.
  • a pharmaceutically acceptable carrier that comprises about 10% (w/v) to about 50% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and optionally an antioxidant.
  • the invention provides topical compositions that comprise a combination of about 0.1% (w/v) to about 5% (w/v) of abamectin and about 1% (w/v) to about 10% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 10% (w/v) to about 50% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and about 0.01% (w/v) to about 2% (w/v) of butylated hydroxytoluene or butylated hydroxyanisole.
  • the invention provides topical compositions that comprise a combination of about 0.1% (w/v) to about 5% (w/v) of abamectin and about 1% (w/v) to about 10% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 10% (w/v) to about 50% (w/v) N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.) and about 0.01% (w/v) to about 2% (w/v) of butylated hydroxytoluene.
  • the invention provides topical compositions that comprise about 0.1% (w/v) to about 2% (w/v) of an avermectin or milbemycin active agent in combination with about 1% (w/v) to about 5% (w/v) of a neonicotinoid active agent, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 20% (w/v) to about 40% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), and optionally an antioxidant.
  • a pharmaceutically acceptable carrier that comprises about 20% (w/v) to about 40% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), and optionally an antioxidant.
  • the invention provides topical compositions that comprise about 0.1% (w/v) to about 2% (w/v) of at least one avermectin or milbemycin active agent selected from the group consisting of abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, moxidectin and nemadectin, or a mixture thereof, in combination with about 1% (w/v) to about 5% (w/v) of at least one neonicotinoid active agent selected from the group consisting of acetamiprid, clothianidin, dinotofuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam, or a combination thereof, or pharmaceutical
  • the invention provides topical compositions that comprise a combination of about 0.1% (w/v) to about 2% (w/v) of abamectin and about 1% (w/v) to about 5% (w/v) imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 20% (w/v) to about 40% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), and optionally an antioxidant.
  • a pharmaceutically acceptable carrier that comprises about 20% (w/v) to about 40% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), and optionally an antioxidant.
  • the invention provides topical compositions that comprise about 0.1% (w/v) to about 2% (w/v) of abamectin and about 1% (w/v) to about 5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 20% (w/v) to about 40% (w/v) of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec- butylpyrrolidone, 1-t-butylpyrrolidone, 1-n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2- pyrrolidone, 1-cyclohex
  • the invention provides topical compositions that comprise about 0.1% (w/v) to about 2% (w/v) of abamectin and about 1% (w/v) to about 5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 20% (w/v) to about 40% (w/v) of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec- butylpyrrolidone, 1-t-butylpyrrolidone, 1-n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2- pyrrolidone, 1-cyclohex
  • the invention provides topical compositions that comprise about 0.1% (w/v) to about 2% (w/v) abamectin and about 1% (w/v) to about 5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 20% (w/v) to about 40% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and optionally an antioxidant.
  • a pharmaceutically acceptable carrier that comprises about 20% (w/v) to about 40% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and optionally an antioxidant.
  • the invention provides topical compositions that comprise a combination of about 0.1% (w/v) to about 2% (w/v) of abamectin and about 1% (w/v) to about 5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 20% (w/v) to about 40% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and about 0.01% (w/v) to about 1% (w/v) of butylated hydroxytoluene or butylated hydroxyanisole.
  • the invention provides topical compositions that comprise a combination of about 0.1% (w/v) to about 2% (w/v) of abamectin and about 1% (w/v) to about 5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 20% (w/v) to about 40% (w/v) N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and about 0.01% (w/v) to about 1% (w/v) of butylated hydroxytoluene.
  • the invention provides topical compositions that comprise about 0.1% (w/v) to about 1% (w/v) of an avermectin or milbemycin active agent in combination with about 2% (w/v) to about 4% (w/v) of a neonicotinoid active agent, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 25% (w/v) to about 35% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), and optionally an antioxidant.
  • a pharmaceutically acceptable carrier that comprises about 25% (w/v) to about 35% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), and optionally an antioxidant.
  • the invention provides topical compositions that comprise about 0.1% (w/v) to about 1% (w/v) of at least one avermectin or milbemycin active agent selected from the group consisting of abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, moxidectin and nemadectin, or a mixture thereof, in combination with about 2% (w/v) to about 4% (w/v) of at least one neonicotinoid active agent selected from the group consisting of acetamiprid, clothianidin, dinotofuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam, or a combination thereof, or pharmaceutical
  • the invention provides topical compositions that comprise a combination of about 0.1% (w/v) to about 1% (w/v) of abamectin and about 2% (w/v) to about 4% (w/v) imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 25% (w/v) to about 35% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s., quantum sufficit), and optionally an antioxidant.
  • a pharmaceutically acceptable carrier that comprises about 25% (w/v) to about 35% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s., quantum sufficit), and optionally an antioxidant.
  • the invention provides topical compositions that comprise about 0.1% (w/v) to about 1% (w/v) of abamectin and about 2% (w/v) to about 4% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 25% (w/v) to about 35% (w/v) of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec- butylpyrrolidone, 1-t-butylpyrrolidone, 1-n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2- pyrrolidone, 1-cyclohe
  • the invention provides topical compositions that comprise about 0.1% (w/v) to about 1% (w/v) of abamectin and about 2% (w/v) to about 4% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 25% (w/v) to about 35% (w/v) of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec- butylpyrrolidone, 1-t-butylpyrrolidone, 1-n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2- pyrrolidone, 1-cyclohe
  • the invention provides topical compositions that comprise about 0.1% (w/v) to about 1% (w/v) abamectin and about 2% (w/v) to about 4% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 25% (w/v) to about 35% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and optionally an antioxidant.
  • the invention provides topical compositions that comprise a combination of about 0.1% (w/v) to about 1% (w/v) of abamectin and about 2% (w/v) to about 4% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 25% (w/v) to about 35% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and about 0.01% (w/v) to about 0.5% (w/v) of butylated hydroxytoluene or butylated hydroxyanisole.
  • the invention provides topical compositions that comprise a combination of about 0.1% (w/v) to about 1% (w/v) of abamectin and about 2% (w/v) to about 4% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 25% (w/v) to about 35% (w/v) N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.) and about 0.01% (w/v) to about 0.5% (w/v) of butylated hydroxytoluene.
  • the invention provides topical compositions that comprise a combination of about 0.4% (w/v) of abamectin and about 3.5% (w/v) imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 30% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s., quantum sufficit), and optionally an antioxidant.
  • a pharmaceutically acceptable carrier that comprises about 30% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s., quantum sufficit), and optionally an antioxidant.
  • the invention provides topical compositions that comprise about 0.4% (w/v) of abamectin and about 3.5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 30% (w/v) of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1- dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t-butylpyrrolidone, 1- n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2-pyrrolidone, 1-cyclohexylpyrrolidone, 1- (2-hydroxyethyl)-pyrrolidone, 1-3-
  • the invention provides topical compositions that comprise about 0.4% (w/v) of abamectin and about 3.5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 30% (w/v) of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1- dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t-butylpyrrolidone, 1- n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2-pyrrolidone, 1-cyclohexylpyrrolidone, 1- (2-hydroxyethyl)-pyrrolidone, 1-3-
  • the invention provides topical compositions that comprise about 0.4% (w/v) abamectin and about 3.5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 30% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and optionally an antioxidant.
  • the invention provides topical compositions that comprise a combination of about 0.4% (w/v) of abamectin and about 3.5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that comprises about 30% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and about 0.1% (w/v) of butylated hydroxytoluene.
  • the invention provides topical compositions consisting essentially of about 0.1% (w/v) to about 5% (w/v) of an avermectin or milbemycin active agent in combination with about 1% (w/v) to about 10% (w/v) of a neonicotinoid active agent, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 10% (w/v) to about 50% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s., quantum sufficit), and optionally an antioxidant.
  • a pharmaceutically acceptable carrier that consists essentially of about 10% (w/v) to about 50% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s., quantum sufficit), and optionally an antioxidant.
  • the invention provides topical compositions consisting essentially of about 0.1% (w/v) to about 5% (w/v) of at least one avermectin or milbemycin active agent selected from the group consisting of abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, moxidectin and nemadectin, or a mixture thereof, in combination with about 1% (w/v) to about 10% (w/v) of at least one neonicotinoid active agent selected from the group consisting of acetamiprid, clothianidin, dinotofuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam, or a combination thereof,
  • the invention provides topical compositions consisting essentially of a combination of about 0.1% (w/v) to about 5% (w/v) of abamectin and about 1% (w/v) to about 10% (w/v) imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 10% (w/v) to about 50% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), and optionally an antioxidant.
  • the invention provides topical compositions consisting essentially of about 0.1% (w/v) to about 5% (w/v) of abamectin and about 1% (w/v) to about 10% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 10% (w/v) to about 50% (w/v) of a pyrrolidone solvent selected from the group consisting of 2- pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1- dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t-butylpyrrolidone, 1- n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2-pyrrolidone
  • the invention provides topical compositions consisting essentially of about 0.1% (w/v) to about 5% (w/v) of abamectin and about 1% (w/v) to about 10% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 10% (w/v) to about 50% (w/v) of a pyrrolidone solvent selected from the group consisting of 2- pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1- dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t-butylpyrrolidone, 1- n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2-pyrrolidone
  • the invention provides topical compositions consisting essentially of about 0.1% (w/v) to about 5% (w/v) of abamectin and about 1% (w/v) to about 10% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 10% (w/v) to about 50% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and optionally an antioxidant.
  • the invention provides topical compositions consisting essentially of a combination of about 0.1% (w/v) to about 5% (w/v) of abamectin and about 1% (w/v) to about 10% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 10% (w/v) to about 50% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and about 0.01% (w/v) to about 2% (w/v) of butylated hydroxytoluene or butylated hydroxyanisole.
  • the invention provides topical compositions consisting essentially of a combination of about 0.1% (w/v) to about 5% (w/v) of abamectin and about 1% (w/v) to about 10% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 10% (w/v) to about 50% (w/v) N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), about 0.01% (w/v) to about 2% (w/v) of butylated hydroxytoluene.
  • the invention provides topical compositions consisting essentially of about 0.1% (w/v) to about 2% (w/v) of an avermectin or milbemycin active agent in combination with about 1% (w/v) to about 5% (w/v) of a neonicotinoid active agent, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 20% (w/v) to about 40% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), and optionally an antioxidant.
  • the invention provides topical compositions consisting essentially of about 0.1% (w/v) to about 2% (w/v) of at least one avermectin or milbemycin active agent selected from the group consisting of abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, moxidectin and nemadectin, or a mixture thereof, in combination with about 1% (w/v) to about 5% (w/v) of at least one neonicotinoid active agent selected from the group consisting of acetamiprid, clothianidin, dinotofuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam, or a combination thereof
  • the invention provides topical compositions consisting essentially of a combination of about 0.1% (w/v) to about 2% (w/v) of abamectin and about 1% (w/v) to about 5% (w/v) imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 20% (w/v) to about 40% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s., quantum sufficit), and optionally an antioxidant.
  • a pharmaceutically acceptable carrier that consists essentially of about 20% (w/v) to about 40% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s., quantum sufficit), and optionally an antioxidant.
  • the invention provides topical compositions consisting essentially of about 0.1% (w/v) to about 2% (w/v) of abamectin and about 1% (w/v) to about 5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 20% (w/v) to about 40% (w/v) of a pyrrolidone solvent selected from the group consisting of 2- pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1- dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t-butylpyrrolidone, 1- n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2-pyrrolidon
  • the invention provides topical compositions consisting essentially of about 0.1% (w/v) to about 2% (w/v) of abamectin and about 1% (w/v) to about 5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 20% (w/v) to about 40% (w/v) f a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1-dodecylpyrrolidone, 1- isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t-butylpyrrolidone, 1-n-butylpyrrolidone, 1- hexylpyrrolidone, 1-vinyl-2-pyrroli
  • the invention provides topical compositions consisting essentially of about 0.1% (w/v) to about 2% (w/v) abamectin and about 1% (w/v) to about 5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 20% (w/v) to about 40% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and optionally an antioxidant.
  • the invention provides topical compositions consisting essentially of a combination of about 0.1% (w/v) to about 2% (w/v) of abamectin and about 1% (w/v) to about 5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 20% (w/v) to about 40% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and about 0.01% (w/v) to about 1% (w/v) of butylated hydroxytoluene or butylated hydroxyanisole.
  • the invention provides topical compositions consisting essentially of a combination of about 0.1% (w/v) to about 2% (w/v) of abamectin and about 1% (w/v) to about 5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 20% (w/v) to about 40% (w/v) N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), about 0.01% (w/v) to about 1% (w/v) of butylated hydroxytoluene.
  • the invention provides topical compositions consisting essentially of about 0.1% (w/v) to about 1% (w/v) of an avermectin or milbemycin active agent in combination with about 2% (w/v) to about 4% (w/v) of a neonicotinoid active agent, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 25% (w/v) to about 35% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s., quantum sufficit), and optionally an antioxidant.
  • a pharmaceutically acceptable carrier that consists essentially of about 25% (w/v) to about 35% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s., quantum sufficit), and optionally an antioxidant.
  • the invention provides topical compositions consisting essentially of about 0.1% (w/v) to about 1% (w/v) of at least one avermectin or milbemycin active agent selected from the group consisting of abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, moxidectin and nemadectin, or a mixture thereof, in combination with about 2% (w/v) to about 4% (w/v) of at least one neonicotinoid active agent selected from the group consisting of acetamiprid, clothianidin, dinotofuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam, or a combination thereof
  • the invention provides topical compositions consisting essentially of a combination of about 0.1% (w/v) to about 1% (w/v) of abamectin and about 2% (w/v) to about 4% (w/v) imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 25% (w/v) to about 35% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), and optionally an antioxidant.
  • the invention provides topical compositions consisting essentially of about 0.1% (w/v) to about 1% (w/v) of abamectin and about 2% (w/v) to about 4% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 25% (w/v) to about 35% (w/v) of a pyrrolidone solvent selected from the group consisting of 2- pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1- dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t-butylpyrrolidone, 1- n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2-pyrroli
  • the invention provides topical compositions consisting essentially of about 0.1% (w/v) to about 1% (w/v) of abamectin and about 2% (w/v) to about 4% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 25% (w/v) to about 35% (w/v) of a pyrrolidone solvent selected from the group consisting of 2- pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1- dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t-butylpyrrolidone, 1- n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2-pyrroli
  • the invention provides topical compositions consisting essentially of about 0.1% (w/v) to about 1% (w/v) abamectin and about 2% (w/v) to about 4% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 25% (w/v) to about 35% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and optionally an antioxidant.
  • the invention provides topical compositions consisting essentially of a combination of about 0.1% (w/v) to about 1% (w/v) of abamectin and about 2% (w/v) to about 4% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 25% (w/v) to about 35% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and about 0.01% (w/v) to about 0.5% (w/v) of butylated hydroxytoluene or butylated hydroxyanisole.
  • the invention provides topical compositions consisting essentially of a combination of about 0.1% (w/v) to about 1% (w/v) of abamectin and about 2% (w/v) to about 4% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 25% (w/v) to about 35% (w/v) N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), about 0.01% (w/v) to about 0.05% (w/v) of butylated hydroxytoluene.
  • the invention provides topical compositions consisting essentially of a combination of about 0.4% (w/v) of abamectin and about 3.5% (w/v) imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 30% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s., quantum sufficit), and optionally an antioxidant.
  • the invention provides topical compositions consisting essentially of about 0.4% (w/v) of abamectin and about 3.5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 30% (w/v) of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec- butylpyrrolidone, 1-t-butylpyrrolidone, 1-n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2- pyrrolidone, 1-cyclohexylpyrrolidone, 1-(2-hydroxyethyl)-pyrrolidone
  • the invention provides topical compositions consisting essentially of about 0.4% (w/v) of abamectin and about 3.5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 30% (w/v) of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1-dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec- butylpyrrolidone, 1-t-butylpyrrolidone, 1-n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2- pyrrolidone, 1-cyclohexylpyrrolidone, 1-(2-hydroxyethyl)-pyrrolidone
  • the invention provides topical compositions consisting essentially of about 0.4% (w/v) abamectin and about 3.5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 30% (w/v) of N- methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and optionally an antioxidant.
  • the invention provides topical compositions consisting essentially of a combination of about 0.4% (w/v) of abamectin and about 3.5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 30% (w/v) of N- methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and about 0.1% (w/v) of butylated hydroxytoluene.
  • the invention provides topical compositions consisting of about 0.1% (w/v) to about 5% (w/v) of an avermectin or milbemycin active agent in combination with about 1% (w/v) to about 10% (w/v) of a neonicotinoid active agent, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 10% (w/v) to about 50% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), an antioxidant and a dye.
  • a pharmaceutically acceptable carrier that consists of about 10% (w/v) to about 50% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), an antioxidant and a dye.
  • the invention provides topical compositions consisting of about 0.1% (w/v) to about 5% (w/v) of at least one avermectin or milbemycin active agent selected from the group consisting of abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, moxidectin and nemadectin, or a mixture thereof, in combination with about 1% (w/v) to about 10% (w/v) of at least one neonicotinoid active agent selected from the group consisting of acetamiprid, clothianidin, dinotofuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam, or a combination thereof, or pharmaceutical
  • the invention provides topical compositions consisting of a combination of about 0.1% (w/v) to about 5% (w/v) of abamectin and about 1% (w/v) to about 10% (w/v) imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 10% (w/v) to about 50% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), an antioxidant and a dye.
  • a pharmaceutically acceptable carrier that consists of about 10% (w/v) to about 50% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), an antioxidant and a dye.
  • the invention provides topical compositions consisting of about 0.1% (w/v) to about 5% (w/v) of abamectin and about 1% (w/v) to about 10% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 10% (w/v) to about 50% (w/v) of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N- methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1-dodecylpyrrolidone, 1- isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t-butylpyrrolidone, 1-n-butylpyrrolidone, 1- hexylpyrrolidone, 1-vinyl-2-pyrrolidone,
  • the invention provides topical compositions consisting of about 0.1% (w/v) to about 5% (w/v) of abamectin and about 1% (w/v) to about 10% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 10% (w/v) to about 50% (w/v) of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N- methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1-dodecylpyrrolidone, 1- isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t-butylpyrrolidone, 1-n-butylpyrrolidone, 1- hexylpyrrolidone, 1-vinyl-2-pyrrolidone,
  • the invention provides topical compositions consisting of about 0.1% (w/v) to about 5% (w/v) of abamectin and about 1% (w/v) to about 10% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 10% (w/v) to about 50% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), butylated hydroxy toluene and a dye.
  • a pharmaceutically acceptable carrier that consists of about 10% (w/v) to about 50% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), butylated hydroxy toluene and a dye.
  • the invention provides topical compositions consisting of a combination of about 0.1% (w/v) to about 5% (w/v) of abamectin and about 1% (w/v) to about 10% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 10% (w/v) to about 50% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), about 0.01% (w/v) to about 2% (w/v) of butylated hydroxytoluene or butylated hydroxyanisole and a dye.
  • the invention provides topical compositions consisting of a combination of about 0.1% (w/v) to about 5% (w/v) of abamectin and about 1% (w/v) to about 10% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 10% (w/v) to about 50% (w/v) N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), about 0.01% (w/v) to about 2% (w/v) of butylated hydroxytoluene and a dye.
  • the invention provides topical compositions consisting of about 0.1% (w/v) to about 2% (w/v) of an avermectin or milbemycin active agent in combination with about 1% (w/v) to about 5% (w/v) of a neonicotinoid active agent, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 20% (w/v) to about 40% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), an antioxidant and a dye.
  • a pharmaceutically acceptable carrier that consists of about 20% (w/v) to about 40% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), an antioxidant and a dye.
  • the invention provides topical compositions consisting of about 0.1% (w/v) to about 2% (w/v) of at least one avermectin or milbemycin active agent selected from the group consisting of abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, moxidectin and nemadectin, or a mixture thereof, in combination with about 1% (w/v) to about 5% (w/v) of at least one neonicotinoid active agent selected from the group consisting of acetamiprid, clothianidin, dinotofuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam, or a combination thereof, or
  • the invention provides topical compositions consisting of a combination of about 0.1% (w/v) to about 2% (w/v) of abamectin and about 1% (w/v) to about 5% (w/v) imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 20% (w/v) to about 40% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), an antioxidant and a dye.
  • a pharmaceutically acceptable carrier that consists of about 20% (w/v) to about 40% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), an antioxidant and a dye.
  • the invention provides topical compositions consisting of about 0.1% (w/v) to about 2% (w/v) of abamectin and about 1% (w/v) to about 5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 20% (w/v) to about 40% (w/v) of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N- methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1-dodecylpyrrolidone, 1- isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t-butylpyrrolidone, 1-n-butylpyrrolidone, 1- hexylpyrrolidone, 1-vinyl-2-pyrrolidone
  • the invention provides topical compositions consisting of about 0.1% (w/v) to about 2% (w/v) of abamectin and about 1% (w/v) to about 5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 20% (w/v) to about 40% (w/v) of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N- methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1-dodecylpyrrolidone, 1- isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t-butylpyrrolidone, 1-n-butylpyrrolidone, 1- hexylpyrrolidone, 1-vinyl-2-pyrrolidone
  • the invention provides topical compositions consisting of about 0.1% (w/v) to about 2% (w/v) abamectin and about 1% (w/v) to about 5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 20% (w/v) to about 40% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), butylated hydroxy toluene and a dye.
  • a pharmaceutically acceptable carrier that consists of about 20% (w/v) to about 40% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), butylated hydroxy toluene and a dye.
  • the invention provides topical compositions consisting of a combination of about 0.1% (w/v) to about 2% (w/v) of abamectin and about 1% (w/v) to about 5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 20% (w/v) to about 40% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and about 0.01% (w/v) to about 1% (w/v) of butylated hydroxy toluene and a dye.
  • a pharmaceutically acceptable carrier that consists essentially of about 20% (w/v) to about 40% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and about 0.01% (w/v) to about 1% (w/v) of butylated hydroxy tol
  • the invention provides topical compositions consisting of a combination of about 0.1% (w/v) to about 2% (w/v) of abamectin and about 1% (w/v) to about 5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 20% (w/v) to about 40% (w/v) N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), about 0.01% (w/v) to about 1% (w/v) of butylated hydroxytoluene and a dye.
  • the invention provides topical compositions consisting of about 0.1% (w/v) to about 1% (w/v) of an avermectin or milbemycin active agent in combination with about 2% (w/v) to about 4% (w/v) of a neonicotinoid active agent, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 25% (w/v) to about 35% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), an antioxidant and a dye.
  • a pharmaceutically acceptable carrier that consists of about 25% (w/v) to about 35% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), an antioxidant and a dye.
  • the invention provides topical compositions consisting of about 0.1% (w/v) to about 1% (w/v) of at least one avermectin or milbemycin active agent selected from the group consisting of abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, moxidectin and nemadectin, or a mixture thereof, in combination with about 2% (w/v) to about 4% (w/v) of at least one neonicotinoid active agent selected from the group consisting of acetamiprid, clothianidin, dinotofuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam, or a combination thereof, or
  • the invention provides topical compositions consisting of a combination of about 0.1% (w/v) to about 1% (w/v) of abamectin and about 2% (w/v) to about 4% (w/v) imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 25% (w/v) to about 35% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), an antioxidant and a dye.
  • a pharmaceutically acceptable carrier that consists of about 25% (w/v) to about 35% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), an antioxidant and a dye.
  • the invention provides topical compositions consisting of about 0.1% (w/v) to about 1% (w/v) of abamectin and about 2% (w/v) to about 4% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 25% (w/v) to about 35% (w/v) of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N- methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1-dodecylpyrrolidone, 1- isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t-butylpyrrolidone, 1-n-butylpyrrolidone, 1- hexylpyrrolidone, 1-vinyl-2-pyrrolidon
  • the invention provides topical compositions consisting of about 0.1% (w/v) to about 1% (w/v) of abamectin and about 2% (w/v) to about 4% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 25% (w/v) to about 35% (w/v) of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N- methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1-dodecylpyrrolidone, 1- isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t-butylpyrrolidone, 1-n-butylpyrrolidone, 1- hexylpyrrolidone, 1-vinyl-2-pyrrolidone,
  • the invention provides topical compositions consisting of about 0.1% (w/v) to about 1% (w/v) abamectin and about 2% (w/v) to about 4% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 25% (w/v) to about 35% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), butylated hydroxy toluene or butylated hydroxyanisole and a dye.
  • a pharmaceutically acceptable carrier that consists of about 25% (w/v) to about 35% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), butylated hydroxy toluene or butylated hydroxyanisole and a dye.
  • the invention provides topical compositions consisting of a combination of about 0.1% (w/v) to about 1% (w/v) of abamectin and about 2% (w/v) to about 4% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 25% (w/v) to about 35% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), and about 0.01% (w/v) to about 0.5% (w/v) of butylated hydroxytoluene or butylated hydroxyanisole and a dye.
  • the invention provides topical compositions consisting of a combination of about 0.1% (w/v) to about 1% (w/v) of abamectin and about 2% (w/v) to about 4% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists essentially of about 25% (w/v) to about 35% (w/v) N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), about 0.01% (w/v) to about 0.05% (w/v) of butylated hydroxytoluene and a dye.
  • the invention provides topical compositions consisting of a combination of about 0.4% (w/v) of abamectin and about 3.5% (w/v) imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 30% (w/v) of a pyrrolidone solvent and a glycol ether solvent (q.s.), 0.1% (w/v) butylated hydroxy toluene and a dye.
  • the invention provides topical compositions consisting of about 0.4% (w/v) of abamectin and about 3.5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 30% (w/v) of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1- dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t-butylpyrrolidone, 1- n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2-pyrrolidone, 1-cyclohexylpyrrolidone, 1- (2-hydroxyethyl)-pyrrolidone,
  • the invention provides topical compositions consisting of about 0.4% (w/v) of abamectin and about 3.5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 30% (w/v) of a pyrrolidone solvent selected from the group consisting of 2-pyrrolidone, N-methylpyrrolidone, 1-ethylpyrrolidone, l-octylpyrrolidone, 1- dodecylpyrrolidone, 1-isopropylpyrrolidone, l-sec-butylpyrrolidone, 1-t-butylpyrrolidone, 1- n-butylpyrrolidone, 1-hexylpyrrolidone, 1-vinyl-2-pyrrolidone, 1-cyclohexylpyrrolidone, 1- (2-hydroxyethyl)-pyrrolidone,
  • the invention provides topical compositions consisting of about 0.4% (w/v) abamectin and about 3.5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 30% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), 0.1% (w/v) of butylated hydroxy toluene or butylated hydroxyanisole and a dye.
  • the invention provides topical compositions consisting of a combination of about 0.4% (w/v) of abamectin and about 3.5% (w/v) of imidacloprid, or pharmaceutically acceptable salts, hydrates or solvates thereof, together with a pharmaceutically acceptable carrier that consists of about 30% (w/v) of N-methylpyrrolidone and dipropylene glycol monomethyl ether (q.s.), about 0.1% (w/v) of butylated hydroxytoluene and a dye.
  • compositions of the invention which include two different active agents in a carrier system that is compatible with each active agent, have been surprisingly discovered to be stable, to have an extended shelf-life, and to be effective against a broad spectrum of ectoparasites and/or endoparasites. It will be well apparent to one of skill in the art that combination of two active agents in a single composition without affecting the stability of the active agents during storage or the efficacy of each active upon administration is extremely difficult and unpredictable.
  • the two classes of active agents included in the inventive compositions have substantially different structures and consequently have different solubility and stability requirements.
  • compositions of the present invention combine active agents that are efficacious against internal and/or external parasites.
  • the compositions of the invention which in some embodiments are in the form of topical solutions in a homogeneous carrier, are unique in that they achieve excellent efficacy against external parasites, such as lice and fly, and effectively controlling internal parasites such as gastrointestinal nematodes and other parasitic worms.
  • the compositions of the invention surprisingly achieve the required distribution of an effective amount each different active to the site of the animal required to achieve the superb efficacy against harmful internal and/or external parasites.
  • Penetration enhancers include compounds with a polar head group and long alkyl chains such as non-ionic surfactants, oleic acid, propylene glycol, decyl methyl sulfoxide and Azone ® , among others.
  • the composition will be in the form of a liquid solution or suspension.
  • the pharmaceutically acceptable carrier may be any suitable carrier or diluent commonly used in the formulation art including aqueous or organic solvents or mixtures of solvents. These organic solvents may be found, for example, in Remington Pharmaceutical Sciences, 16 th Edition (1986). Organic solvents that can be used in the invention include the pyrrolidone and glycol ether solvents described above.
  • Suitable solvents include but are not limited to: acetyltributyl citrate, oleic acid, fatty acid esters such as the dimethyl ester; dialkylesters of dicarboxylic acids including, but not limited to, diisobutyl adipate, diisopropyl adipate (also known as CERAPHYL 230), diethyl sebacate, diisopropyl sebacate, dibutyl sebacate, and the like; ketones including acetone, methylisobutyl ketone (MIK) and methyl ethyl ketone and the like, acetonitrile, benzyl alcohol, methanol, ethyl alcohol, isopropanol, butanol, aromatic ethers such as anisole, amides including dimethylacetamide and dimethylformamide, dimethyl sulfoxide, ethylene glycol, propylene glycol, glycol carbonates, monomethylacetamide, liquid polyoxyethylene glyco
  • solvents can be supplemented by various excipients according to the nature of the desired phases, such as C8-C10 caprylic/capric triglyceride (ESTASAN or MIGLYOL 812), oleic acid or propylene glycol.
  • C8-C10 caprylic/capric triglyceride ESTASAN or MIGLYOL 812
  • oleic acid oleic acid
  • propylene glycol propylene glycol
  • the pharmaceutically acceptable carrier of the formulation comprises C 1 -C 10 alcohols or esters thereof (including acetates, such as ethyl acetate and the like), C10-C18 saturated fatty acids or esters thereof, C10-C18 monounsaturated fatty acids or esters thereof, monoesters or diesters of aliphatic diacids, or mixtures thereof.
  • the carrier or diluent includes a derivative of glycerol including, but not limited to, glycerol monoesters (e.g. monoglycerides), glycerol diesters (e.g. diglycerides), glycerol triesters (e.g. triglycerides such as triacetin), or glycerol formal, or mixtures thereof.
  • Glycerol formal is a mixture of 5-hydroxy-1,3-dioxane and 4- hydroxymethyl-1,3- dioxolane (approximately 60:40), which are cyclic ether compounds derived from glycerol and having 2 oxygen atoms in the ring structure and substituted by alcohol group.
  • Glycerol Formal is a low odor and low toxic solvent for a wide variety of applications in pharmaceutical and cosmetics industry including anti-parasite veterinary formulations.
  • the carrier may include C1-C10 esters of carboxylic acids such as butyl or octyl acetate.
  • the carrier may comprise dimethyl isosorbide.
  • Dimethyl Isosorbide (DMI) is a high purity solvent and carrier which offers a safe, effective delivery enhancement mechanism for active ingredients in personal care products and pharmaceutical formulations.
  • dimethyl isosorbide is sometimes used as an epidermal penetration enhancer to provide enhanced penetration of active agents to the epidermis. It may also provide delivery of active agents into the skin while avoiding crystallization of the active agent, which will severely limit the effectiveness of the formulation.
  • Dimethyl Isosorbide is soluble in a variety of ingredients including water, cottonseed oil, isopropanol, isopropyl myristate, propylene glycol, polysorbate 20, and polysorbate 80. It is insoluble in hydrogenated castor oil, lanolin, mineral oils or silicone oil (dimethicone).
  • the carrier or diluent may include dimethyl sulfoxide (DMSO), glycol derivatives such as, for example, propylene glycol, polyethylene glycols or glycerol.
  • DMSO dimethyl sulfoxide
  • glycol derivatives such as, for example, propylene glycol, polyethylene glycols or glycerol.
  • vehicle or diluent mention may also be made of plant oils such as, but not limited to soybean oil, groundnut oil, castor oil, corn oil, cotton oil, olive oil, grape seed oil, sunflower oil, etc.; mineral oils such as, but not limited to, petrolatum, paraffin, silicone, etc.; aliphatic or cyclic hydrocarbons or alternatively, for example, medium-chain (such as C 8 to C 12 ) triglycerides, or mixtures thereof.
  • compositions suitable for topical administration to an animal are provided.
  • Topical, dermal and subdermal formulations can include emulsions, creams, ointments, gels, pastes, powders, shampoos, spot-on and pour-on solutions, emulsions and suspension formulations and ready-to-use formulations.
  • compositions of the invention are in the form of a spot-on formulation that is applied to a localized area on an animal, rather than the entire coat of the animal or a large portion of the animal’s coat.
  • a localized region the location is between the shoulders.
  • the spot-on formulation according to the present invention provide long-lasting and broad-spectrum efficacy against ectoparasites and/or endoparasites when the solution is applied to the mammal or bird.
  • the spot-on formulations provide for topical administration of a concentrated solution, suspension, microemulsion or emulsion for intermittent application to a spot on the animal, generally between the two shoulders (solution of spot-on type).
  • Spot-on formulations are well known techniques for topically delivering an antiparasitic agent to a limited area of the host.
  • U.S. Patent Nos. 5,045,536 6,426,333; 6,482,425; 6,962,713; and 6,998,131 all incorporated herein by reference, describe spot-on formulations.
  • WO 01/957715 also incorporated herein by reference, describes a method for controlling ectoparasites in small rodents as well as interrupting or preventing the diseases caused by arthropods in small rodents, which comprise applying topical formulations, such as spot-on compositions, to the skin, or hair of the rodents.
  • the pharmaceutically acceptable carrier may be a liquid carrier vehicle as described herein, and other carriers described in the art, for example in U.S. Patent No. 6,426,333, which is incorporated herein by reference.
  • the liquid carrier vehicle can optionally contain a crystallization inhibitor such as the crystallization inhibitors to inhibit the formation of crystals or precipitate of the active components.
  • Spot-on formulations may be prepared by dissolving the active ingredients into the pharmaceutically or veterinary acceptable vehicle.
  • the spot-on formulation can be prepared by encapsulation of the active ingredients to leave a residue of the therapeutic agent on the surface of the animal.
  • These formulations will vary with regard to the weight of the therapeutic agent in the combination depending on the species of host animal to be treated, the severity and type of infection and the body weight of the host.
  • Pour-on formulations are described, for example, in U.S. Patent No.6,010,710, which is incorporated herein by reference.
  • Pour-on formulations generally comprise a diluent or vehicle which may include a solvent (e.g. an organic solvent) described herein to dissolve the active agent.
  • Some pour-on formulations may include oily carriers while other pour-on formulations may be in hydrophilic carriers.
  • Pour-on formulation may be administered to livestock animals such as cattle and sheep.
  • pour-on formulations are administered to the animal as a stripe to an external surface of the animal, e.g. a stripe from head to tail of the animal.
  • the process comprises applying the solution to livestock animals before they arrive in the Feed Lot, it being possible for this application to be the final one before the animals are slaughtered.
  • the veterinarily acceptable carrier for the topical compositions of the invention will generally comprise a diluent or vehicle in which the active agents are soluble.
  • the formulations may include organic solvents such as those described herein for the macrocyclic lactone active agent and the neonicotinoid. Preferred solvents include pyrrolidone solvents and glycol ether solvents and combinations thereof. It will be apparent to those of skill in the art that the carrier or diluent of the topical compositions must be able to deliver the active agents to the targeted location without the active agents precipitating from solution or forming crystals.
  • the carrier or diluent of the compositions will be suitable to avoid precipitation or crystallization of the active agents.
  • the compositions may include a crystallization inhibitor in addition to the carrier or diluent.
  • an emollient and/or spreading and/or film-forming agent may be added to the topical compositions of the invention.
  • the emollient and/or spreading and/or film-forming agents include:
  • polyvinylpyrrolidone polyvinyl alcohols, copolymers of vinyl acetate and vinylpyrrolidone, polyethylene glycols, benzyl alcohol, mannitol, glycerol, sorbitol, polyoxyethylenated sorbitan esters; lecithin, sodium carboxymethylcellulose, silicone oils, polydiorganosiloxane oils (such as polydimethylsiloxane (PDMS) oils), for example those containing silanol functionalities, or a 45V2 oil,
  • PDMS polydimethylsiloxane
  • anionic surfactants such as alkaline stearates, sodium, potassium or ammonium stearates; calcium stearate, triethanolamine stearate; sodium abietate; alkyl sulfates (e.g. sodium lauryl sulfate and sodium cetyl sulfate); sodium dodecyl benzenesulfonate, sodium dioctylsulphosuccinate; fatty acids (e.g. those derived from coconut oil),
  • cationic surfactants such as water-soluble quaternary ammonium salts of formula N + R'R"R"'R""Y-, in which the R radicals are optionally hydroxylated hydrocarbon radicals and Y- is an anion of a strong acid such as the halide, sulfate and sulfonate anions; cetyltrimethylammonium bromide is among the cationic surfactants which can be used,
  • nonionic surfactants such as sorbitan esters, which are optionally polyoxyethylenated (e.g. polysorbate 80), polyoxyethylenated alkyl ethers; polyoxypropylated fatty alcohols such as polyoxypropylene-styrol ether; polyethylene glycol stearate, polyoxyethylenated derivatives of castor oil, polyglycerol esters, polyoxyethylenated fatty alcohols, polyoxyethylenated fatty acids, copolymers of ethylene oxide and propylene oxide, (f) amphoteric surfactants such as the substituted lauryl compounds of betaine, and (g) a mixture of at least two of these agents.
  • sorbitan esters which are optionally polyoxyethylenated (e.g. polysorbate 80), polyoxyethylenated alkyl ethers; polyoxypropylated fatty alcohols such as polyoxypropylene-styrol
  • the emollient is used in a proportion of from about 0.1 to about 10%, or about 0.25 to about 5% (w/v).
  • the volume of the topical composition applied is not restricted as long as the amount of substance administered is shown to be safe and efficacious. Typically, the volume applied depends on the size and weight of the animal as well as the concentration of active, the extent of infestation by parasites and the type of administration. For spot-on compositions, the volume applied is typically of the order of about 0.1 to about 1 ml, or about 0.1 ml to about 5 ml, or about 0.1 ml to about 10 ml. In other embodiments, the volume may be about 4 ml to about 7 ml. For larger animals, the volume may be higher including, but not limited to, up to 10 ml, up to 20 ml or up to 30 ml, or higher.
  • the volume is on the order of about 0.5 ml to about 1 ml or about 0.5 ml to about 2 ml for cats, and on the order of about 0.3 to about 3 ml or 4 ml for dogs, depending on the weight of the animal.
  • the volume of the spot-on composition for administration to cats is about 0.3 ml. In another embodiment, the volume is about 0.9 ml.
  • volume application rate of about 0.5 ml to about 2 ml of the composition per kg of the animal is administered. In one embodiment, a volume of about 1 ml to about 1.5 ml of the pour-on composition per kg body weight is administered. Typically, the volume applied can be of the order of about 10 to about 100 mL. In other embodiments, volume applied of the pour-on formulations may be about 20 ml to about 90 ml, about 30 ml to about 80 ml or about 40 ml to about 70 ml. In still other embodiments, the volume may be about 45 ml to about 65ml. In certain embodiments, the volume is about 40 ml or about 60 ml.
  • a method for preventing or treating a parasite infestation/infection in an animal comprising administering a composition described herein, for example, a composition comprising an effective amount of at least one macrocyclic lactone active agent in combination with at least one neonicotinoid agent, together with a pharmaceutically acceptable carrier, and optionally an antioxidant and/or a penetration enhancer.
  • the compositions or formulations of the invention have an extended shelf-life and a long-lasting efficacy against endoparasites and/or ectoparasites (e.g. lice and fly) that harm animals.
  • the compositions or formulations of the invention are also rainfast, and provide persistency/prevention of reinfection against ectoparasites such as lice for up to 5 weeks following treatment.
  • methods for the treatment or prevention of a parasitic infestation or infection in a an animal comprise administering a composition comprising an effective amount of at least one macrocyclic lactone active agent and at least one neonicotinoid active agent to the animal.
  • Ectoparasites against which the methods and compositions of the invention are effective include, but are not limited to, lice, fleas, mites, mosquitoes and flies.
  • the compositions and methods of the invention are also effective against endoparasites including, but not limited to, cestodes, nematodes, hookworms and roundworms of the digestive tract of animals and humans and filarial worms such as Dirofilaria immitis (heartworm).
  • the methods of the invention exhibit excellent efficacy against sheep body lice (Bovicola ovis) while at the same time exhibiting superior efficacy against the gastrointestinal nematodes Haemonchus contortus, Telodorsagia circumcinta and Trichostrongylus colubriformis.
  • the invention provides methods for the treatment and prevention of parasitic infections and infestations of animals (either wild or domesticated), including livestock and companion animals such as cats, dogs, horses, chickens, sheep, goats, pigs, turkeys and cattle, with the aim of ridding these hosts of parasites commonly encountered by such animals.
  • compositions of the invention are intended the application or administration of a composition of the invention to an animal that has a parasitic infestation for the eradication of the parasite or the reduction of the number of the parasites infesting the animal undergoing treatment. It is noted that the compositions of the invention may be used to prevent such a parasitic infestation.
  • the methods of the invention encompass administering the macrocyclic lactone active agent(s) and the neonicotinoid active agent(s) together in the same carrier or diluent or separately where each active agent or mixtures of the active agents are present in their own carriers or diluents.
  • the macrocyclic lactone active agent(s) may be administered at the same location on the animal at the same time as the neonicotinoid active agent(s), or the macrocyclic lactone active agent(s) may be administered at a different location on the animal than the neonicotinoid active agent(s).
  • Each active agent may be administered simultaneously or sequentially in separate carriers, which may be the same or different.
  • each of the active compound(s) may be administered by the same mode of administration (e.g. topical, oral, parenteral, etc.), or the different active agents may be administered by different modes of administration.
  • the macrocyclic lactone active agent is abamectin and the neonicotinoid active agent is imidacloprid.
  • the method comprises administering each of the macrocyclic lactone(s) and the neonicotinoid(s) simultaneously.
  • the macrocyclic lactone active agent is abamectin and the neonicotinoid active agent is imidacloprid.
  • the method comprises administering each of the macrocyclic lactone(s) and the neonicotinoid(s) simultaneously in the same carrier or diluent.
  • the macrocyclic lactone active agent is abamectin and the neonicotinoid active agent is imidacloprid.
  • the method comprises administering macrocyclic lactone active agent(s) and the neonicotinoid active agent(s) separately in a separate carrier, which may be the same or different for the two active agents.
  • the macrocyclic lactone active agent is abamectin and the anthelmintic active agent is imidacloprid.
  • a kit for the treatment or prevention of a parasitic infestation in an animal which comprises at least one macrocyclic lactone(s) and at least one neonicotinoid(s) together with a pharmaceutically acceptable carrier that comprises a combination of a pyrrolidione solvent and a glycol ether solvent and a dispensing device for topical application of the composition.
  • the dispensing device may be a pipette, syringes, roll on, droppers, capsules, foil packages, vials, twist tip containers and other single dose and multi- dose containers, which includes an effective dose of each active agent in the pharmaceutically acceptable carrier or diluent.
  • the macrocyclic lactone active agent is abamectin and the anthelmintic active agent is imidacloprid.
  • compositions of the invention may be administered to the animal at different intervals depending on the dose administered.
  • the compositions of the invention may be administered to the animal monthly.
  • the compositions may be administered twice a month or even weekly.
  • Additional veterinary/pharmaceutical active ingredients may be used with the compositions of the invention.
  • the additional active agents may include, but are not limited to, acaricides, anthelmintics, anti-parasitics and insecticides.
  • Anti-parasitic agents can include both ectoparasiticidal and endoparasiticidal agents.
  • Veterinary pharmaceutical agents that may be included in the compositions of the invention are well-known in the art (see e.g. Plumb’ Veterinary Drug Handbook, 5 th Edition, ed. Donald C. Plumb, Blackwell Publishing, (2005) or The Merck Veterinary Manual, 9 th Edition, (January 2005)) and include but are not limited to acarbose, acepromazine maleate, acetaminophen, acetazolamide, acetazolamide sodium, acetic acid, acetohydroxamic acid, acetylcysteine, acitretin, acyclovir, albuterol sulfate, alfentanil, allopurinol, alprazolam, altrenogest, amantadine, amikacin sulfate, aminocaproic acid, aminopentamide hydrogen sulfate, aminophylline/theophylline, amiodarone, amitriptyline, amlodipine
  • additional adulticide insecticides and acaricides can also be added to the composition of the invention.
  • these include pyrethrins (which include cinerin I, cinerin II, jasmolin I, jasmolin II, pyrethrin I, pyrethrin II and mixtures thereof) and pyrethroids, and carbamates (which include but are not limited to benomyl, carbanolate, carbaryl, carbofuran, meththiocarb, metolcarb, promacyl, propoxur, aldicarb, butocarboxim, oxamyl, thiocarboxime and thiofanox).
  • pyrethrins which include cinerin I, cinerin II, jasmolin I, jasmolin II, pyrethrin I, pyrethrin II and mixtures thereof
  • carbamates which include but are not limited to benomyl, carbanolate, carbaryl, carbofuran,
  • Suitable organophosphate active agents include, but are not limited to, coumaphos, trichlorfon, haloxon, naftalofos and dichlorvos, heptenophos, mevinphos, monocrotophos, TEPP, tetrachlorvinphos, and arylpyrazoles, e.g., fipronil.
  • nodulisporic acid and its derivatives may be included in the compositions of the invention. These compounds are used to treat or prevent infections in humans and animals and are described, for example, in U.S. Patent No.5,399,582, 5,962,499, 6,221,894 and 6,399,786, all of which are hereby incorporated by reference in their entirety.
  • the compositions may include one or more of the known nodulisporic acid derivatives in the art, including all stereoisomers, such as those described in the literature cited above.
  • compositions of the invention may include other active agents that are effective against arthropod parasites.
  • Suitable active agents include, but are not limited to, bromocyclen, chlordane, DDT, endosulfan, lindane, methoxychlor, toxaphene, bromophos, bromophos-ethyl, carbophenothion, chlorfenvinphos, chlorpyrifos, crotoxyphos, cythioate, diazinon, dichlorenthion, diemthoate, dioxathion, ethion, famphur, fenitrothion, fenthion, fospirate, iodofenphos, malathion, naled, phosalone, phosmet, phoxim, propetamphos, ronnel, stirofos, allethrin, cyhalothrin, cypermethrin, deltamethr
  • compositions of the invention may advantageously include one or more compounds of the isoxazoline class of compounds.
  • active agents are described in WO 2007/079162, WO 2007/075459 and US 2009/0133319, WO 2007/070606 and US 2009/0143410, WO 2009/003075, WO 2009/002809, WO 2009/024541, WO 2005/085216, US 8466115, US 8853186, US 8383659 and US 2007/0066617 and WO 2008/122375, all of which are incorporated herein by reference in their entirety.
  • an insecticidal agent that can be combined with the compositions of the invention is a semicarbazone, such as metaflumizone.
  • the compositions may include a spinosyn active agent produced by the soil actinomycete Saccharopolyspora spinosa (see, for example Salgado V.L. and Sparks T.C.,“The Spinosyns: Chemistry, Biochemistry, Mode of Action, and Resistance,” in Comprehensive Molecular Insect Science, vol.6, pp.137-173, 2005) or a semi- synthetic spinosoid active agent.
  • a spinosyn active agent produced by the soil actinomycete Saccharopolyspora spinosa (see, for example Salgado V.L. and Sparks T.C.,“The Spinosyns: Chemistry, Biochemistry, Mode of Action, and Resistance,” in Comprehensive Molecular Insect Science, vol.6, pp.137-173, 2005) or a semi- synthetic spinosoid active agent.
  • the spinosyns are typically referred to as factors or components A, B, C, D, E, F, G, H, J, K, L, M, N, 0, P, Q, R, S, T, U, V, W, or Y, and any of these components, or a combination thereof, may be used in the compositions of the invention.
  • the spinosyn compound may be a 5,6,5-tricylic ring system, fused to a 12-membered macro cyclic lactone, a neutral sugar (rhamnose), and an amino sugar (forosamine).
  • spinosyn compounds including 21-butenyl spinosyn produced by Saccharopolyspora pagona, which may be used in the compositions of the invention, may be produced via fermentation by conventional techniques known in the art.
  • Other spinosyn compounds that may be used in the compositions of the invention are disclosed in U.S. Patent Nos. 5,496,931; 5,670,364; 5,591,606; 5,571,901; 5,202,242; 5,767,253; 5,840,861; 5,670,486; 5,631,155 and 6,001,981, all incorporated by reference herein in their entirety.
  • the spinosyn compounds may include, but are not limited to, spinosyn A, spinosyn D, spinosad, spinetoram, or combinations thereof.
  • Spinosad is a combination of spinosyn A and spinosyn D
  • spinetoram is a combination of 3’-ethoxy-5,6-dihydro spinosyn J and 3’-ethoxy spinosyn L.
  • the additional active agent is included in the composition in an amount of between about 0.1 Pg and about 1000 mg. More typically, the additional active agent may be included in a dose of about 10 Pg/kg to about 500 mg/kg body weight (“bwt”), about 1 mg/kg to about 300 mg/kg bwt, about 10 mg/kg to about 200 mg/kg or about 10 mg/kg to about 100 mg/kg bwt. In one embodiment of the invention, the additional active agent is included in a dose of between about 1 Pg/kg and about 10 mg/kg bwt. In other embodiments of the invention, the additional active agent may be included in a dose of about 5 Pg/kg to about 50 mg/kg per weight of the animal.
  • the additional active agent may be present in a dose of about 0.01 mg/kg to about 30 mg/kg, about 0.1 mg/kg to about 20 mg/kg, or about 0.1 mg/kg to about 10 mg/kg of weight of animal. In other embodiments, the additional active agent may be present in a dose of about 5 Pg/kg to about 200 Pg/kg or about 0.1 mg/kg to about 1 mg/kg of weight of animal. In still another embodiment of the invention, the additional active agent is included in a dose between about 0.5 mg/kg to about 50 mg/kg.
  • a fragrance may be added to any of the compositions of the invention.
  • Fragrances which are useful for the invention include but are not limited to:
  • carboxylic acid esters such as octyl acetate, isoamyl acetate, isopropyl acetate and isobutyl acetate;
  • fragrance oils such as lavender oil.
  • compositions of the invention are made by mixing the appropriate amount of the active agents, pharmaceutically acceptable carrier or diluent and optionally a crystallization inhibitor, antioxidant, preservative, film former, etc., to form a composition of the invention.
  • Various forms e.g. tablets, pastes, pour-on, spot-on, collars, etc.
  • of the composition can be obtained by following the method of making these forms described above by the description of making these forms found in general formulation text known to those in the art, e.g.
  • the inventive formulations may contain other inert ingredients such as antioxidants, preservatives, or pH stabilizers. These compounds are well known in the formulation art.
  • Antioxidant such as an alpha tocopherol, ascorbic acid, ascrobyl palmitate, fumaric acid, malic acid, sodium ascorbate, sodium metabisulfate, n-propyl gallate, BHA (butylated hydroxy anisole), BHT (butylated hydroxy toluene) monothioglycerol and the like, may be added to the present formulation.
  • the antioxidants are generally added to the formulation in amounts of from about 0.01 to about 2.0% (w/v), with about 0.05 to about 1.0% (w/v) being especially preferred, and about 0.10% (w/v) being most preferred.
  • the formulations contain an antioxidant.
  • the antioxidant is BHT. In another embodiment, the antioxidant is BHA.
  • Preservatives such as the parabens (methylparaben and/or propylparaben), are suitably used in the formulation in amounts ranging from about 0.01 to about 2.0%, with about 0.05 to about 1.0% being especially preferred.
  • Other preservatives include benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, bronopol, butylparaben, cetrimide, chlorhexidine, chlorobutanol, chlorocresol, cresol, ethylparaben, imidurea, methylparaben, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, potassium sorbate, sodium benzoate, sodium propionate, sorbic acid, thimerosal, and the like. Preferred ranges for these compounds include from about 0.01 to about 5%.
  • Buffering systems include, for example, systems selected from the group consisting of acetic acid/acetate, malic acid/malate, citric acid/citrate, tataric acid/tartrate, lactic acid/lactate, phosphoric acid/phosphate, glycine/glycimate, tris, glutamic acid/glutamates and sodium carbonate.
  • compositions of the invention are administered in parasiticidally effective amounts which are determined by the route of administration, e.g. oral, parenteral, topical, etc.
  • the compounds and compositions of the invention can be applied against a single pest or combinations thereof.
  • compositions of the invention may be administered continuously, for treatment or prevention of parasitic infections or infestations.
  • the compositions of the invention deliver an effective amount of the active compounds to the animal in need thereof to control the target parasites.
  • effective amount is intended a sufficient amount of a composition of the invention to eradicate or reduce the number of parasites infesting the animal.
  • an effective amount of the active agent achieves at least 70% efficacy against the target parasite.
  • an effective amount of the active agent achieves at least 80%, or at least 90% efficacy against the target pests.
  • an effective amount of the active agent will achieve at least 95%, at least 98% or 100% efficacy against the target parasites.
  • a dosage of the neonicotinoid active agent(s) of about 20 mg/kg to about 60 mg/kg of bodyweight is administered. In some embodiments, a dosage of about 30 mg/kg to about 50 mg/kg or about 40 mg/kg to about 50 mg/kg of the neonicotinoid is administered. In one embodiment, the maximum dosage of the neonicotinoid is about 42 mg/kg to about 51 mg/kg of bodyweight. In a preferred embodiment, the maximum dosage of the neonicotinoid administered is about 46.5 mg/kg of bodyweight. It is well within the routine skill of the practitioner to determine a particular dosing regimen for a specific host and parasite.
  • a dosage of about 1 mg/kg to about 10 mg/kg of bodyweight is administered. In some embodiments, a dosage of about 2 mg/kg to about 8 mg/kg or about 3 mg/kg to about 7 mg/kg of the macrocyclic lactone(s) is administered. In one embodiment, the maximum dosage of the macrocyclic lactone(s) is about 4 mg/kg to about 6 mg/kg of bodyweight. In a preferred embodiment, the maximum dosage of the macrocyclic lactone(s) administered is about 5.3 mg/kg of bodyweight. It is well within the routine skill of the practitioner to determine a particular dosing regimen for a specific host and parasite.
  • solutions according to the invention may be applied using any means known per se, e.g. using an applicator gun or a metering flask, pipette, syringes, roll on, droppers, capsules, foil packages, vials, twist tip containers and other single dose and multi-dose containers, EXAMPLES
  • composition of the present invention was formulated as a topical formulation with the specifics shown below in Table 1A.
  • Patent Blue V is a dye present as a scourable marker to assist in stock treatment identification on the farm.
  • Material used in topical formulation 1A was supplied by Vidhi Dyestuffs Mfg Ltd. It contains a minimum of 85% pure dye; no correction was made for dye potency.
  • N-methylpyrrolidone was used as a solvent to dissolve the API’s (imidacloprid and abamectin) before dilution to volume with the dipropylene monomethyl ether vehicle.
  • Table 1B The manufacturing process for the topical formulation is shown in Table 1B.
  • Table 1B Manufacturing Process for Imidacloprid Abamectin Pour On
  • Example 2 study was done to confirm the efficacy (via reductions in total lice counts) of a single dose of 35mg/mL imidacloprid + 4mg/mL abamectin pour-on formulation (according to Table 1) against sheep body lice (Bovicola ovis) when applied at the recommended therapeutic dose level to naturally infected sheep within 24 hours of shearing or 7 days post-shearing.
  • Treatment efficacy was determined by whole body lice counts post treatment and comparison of treated and untreated group mean lice counts.
  • the experimental and observational unit for the study was the individual sheep (female merino breed, 32.0-59.0 kg at treatment, 3-7 years at treatment).
  • the animals were naturally infested with the sheep body louse (Bovicola ovis). Animals that had been treated with persistent lice control products in the previous 6 months, or that were debilitated, suffering from disease or injury, fractious or otherwise unsuitable were excluded from the study. No animals were removed from the study.
  • the investigational veterinary product (“IVP”) was a 35 mg/mL imidacloprid + 4 mg/mL abamectin pour-on formulation as shown in Table 1A, and the maximum dose level was 46.51 mg imidacloprid/kg body weight and 5.32 mg abamectin/kg body weight. Study animals were dosed according to the treatment regime detailed in Table 2 shown below.
  • Group 2 animals were treated within 24 hours of shearing.
  • Group 3 animals were treated 7 days post shearing.
  • the IVP was applied along the back line using the supplied commercial pour on“T-bar” applicator. Because all trial animals were >30kg, the dose of IVP was divided into 2 equal measures and applied as two strips (one each side of the dorsal midline) extending from the mid neck to the tail base. The applicator was verified prior to use and treatment time, calculated dose and applied dose was recorded. Study animals were observed at 2 and 24 hours post-treatment, no clinical abnormalities were observed.
  • Total live lice counts were performed in the groups in the order of Group 2, Group 3 thence Group 1 (untreated animals). Individual lice counts were performed with sheep manually restrained on a ground sheet in the central yard between the group paddocks during counting, with treatment groups being counted separately (with the exception of Day 7, when the animals were brought to the main sheep yards). All sheep in a group were counted before the group was returned to its group paddock and the next group brought into the central yard for counting. The number of live adult and nymph sheep body lice on each individual sheep was counted in a total of 40 wool partings, each parting being approximately 10 cm in length. 20 partings were carried out on the left side of each sheep followed by 20 partings on the right side.
  • a representative sample of lice was removed from the untreated control group after the conclusion of the trial for the purpose of determining the lice populations’ resistance to synthetic pyrethroids (“SP’s”). This was done by exposing a known number of lice to different concentrations of cypermethrin (on calico cloth) for approximately 30 minutes in conditions conducive to their survival (approximately 34oC and greater than 65% humidity). Four concentrations were used (5, 20, 100 and 500 ppm), as well as a control group. Two tests were conducted. After 30 minutes had elapsed the lice were examined under a microscope and assessed as: Alive (walking normally) or
  • Example 3 Efficacy against roundworms (Haemonchus contortus, Telodorsagia
  • Example 3 study was done to confirm the efficacy of a single dose of 35mg/mL imidacloprid + 4mg/mL abamectin pour-on formulation (Investigational Veterinary Product “IVP” see Table 1A) against adult and immature stages of macrocyclic-lactone susceptible strains of Haemonchus contortus, Telodorsagia circumcincta and Trichostrongylus colubriformis in sheep when treated within 24 hours of shearing or up to 7 days post-shearing at the recommended dose level.
  • Treatment efficacy was determined by comparison of treated and untreated group mean Faecal Egg Counts (FECs) and total worm counts.
  • the study was a blinded positive/negative controlled, dose confirmation study using a randomized block design where blocks were based on pre-treatment body weights (Cohort A) or faecal egg counts (Cohort B).
  • the experimental unit was the individual animal, which was Merino male castrate sheep 6-7 months of age (20.5kg to 23.0 kg, at induction) due to their susceptibility to gastrointestinal strongyles at a young age.
  • the treatment regime for Cohorts A and B is shown in Table 5.
  • Treatment data for Cohorts A & B are summarized in Tables 6 and 7, respectively.
  • Table 8a Group mean total worm counts (larval stages at treatment)
  • Table 9a Group mean total worm counts (adult stages at treatment)
  • Example 4 Efficacy against roundworms (Haemonchus contortus, Telodorsagia circumcincta and Trichostrongylus rugatus and Nematodirus spp)
  • Example 4 study was done to confirm the efficacy of a single dose of 35mg/ml imidacloprid + 4mg/ml abamectin pour-on formulation against adult and immature stages of macrocyclic-lactone susceptible strains of Haemonchus contortus, Telodorsagia circumcincta, Trichostrongy/us rugatus and Nematodirus spp in sheep when treated within 24 hours of shearing or up to 7 days post-shearing at the recommended dose level.
  • Treatment efficacy was determined by comparison of treated and untreated group mean Faecal Egg Counts (FECs) and total worm counts.
  • FECs Faecal Egg Counts
  • This study is a second roundworm dose confirmation study utilizing a different suite of macrocyclic lactone susceptible larve to the first roundworm dose confirmation study (Example 3 herein).
  • the nematode strains used in the study were:
  • H.contortus TBZ isolated from the field by CSIRO in 1976; susceptible to all commercial anthelmintics except thiabendazole.
  • Teladorsagia circumcincta 3061 and Trichostrongylus rugatus 3061 obtained by Veterinary Health Research (“VHR”) in 2016 from the Southern Tablelands of NSW as a mixed infection; susceptible to abamectin, resistant to levamisole and albendazole. In this study, none of the T. rugatus larvae established in the control animals, as opposed to T. vitrinus which did establish.
  • VHR Veterinary Health Research
  • Nematodirus spathiger SA isolated by VHR in 2015 from South Australia; susceptible to abamectin.
  • the study was a partially blinded 1 , positive/negative controlled, dose confirmation study using a randomized block design where blocks were based on pre-treatment body weights (Cohort A) or faecal egg counts (Cohort B).
  • the experimental unit was the individual animal, which was Merino male castrated sheep, 6-7 months of age (21.0 kg to 25.0 kg, at induction).
  • the treatment regime for Cohorts A and B is shown in Table 10. Treatment data for Cohorts A and B are summarized in Tables 11 and 12, respectively.
  • Nematodirus spathiger (SA strain) - Day -2
  • Haemonchus contortus strain (TBZ) was mildly resistant to macrocyclic-lactone as both the investigational veterinary product (“IVP”) and positive control both failed to achieve efficacy above 95%.
  • IVP investigational veterinary product
  • VHR Veterinary Health Reseaarch
  • Control of adult Nematodirus spathiger was achieved by the IVP as assessed by TWCR and faecal egg count reduction (“FECR”), as was control of immature stages following treatment with IVP within 24 hours of shearing. Control of the immature stage by the IVP when applied 7 days off shears was demonstrated as assessed by TWCR using geometric means, but not via FECR. This is likely due to the sporadic nature by which N. spathiger lay eggs; only one control animal had a positive Nematodirus FEC on Day 41-42 even though all of the controls were infected as assessed by total worm count.
  • Table 15B Group mean total worm counts (adult stages at time of treatment)
  • Example 5 study was done to confirm the period of persistency (via reductions in total lice counts) of a single dose of 35mg/mL imidacloprid + 4mg/mL abamectin pour-on formulation against sheep body lice (Bovicola ovis) when applied at the proposed therapeutic dose level to naturally infected sheep immediately off-shears subsequently challenged 21 or 28 days post-treatment.
  • Treatment efficacies were determined by comparison of treated and untreated group mean lice counts post-treatment.
  • This study was a non-blinded negative controlled, single site, period of persistency study using a randomized block design where blocks were based on pre-treatment sheep bodyweights– Cohort A or live lice counts– Cohort B.
  • a second cohort of fifty (50) Merino sheep (Cohort B) were selected from
  • Sheep in Group 6 were introduced as challenge animals to Group 1 (between Days 28 and 35), sheep in Group 7 were introduced as challenge animals to Group 2 (between Days 21 and 28), sheep in Group 8 were introduced as challenge animals to Group 3 (between Days 28 and 35), sheep in Group 9 were introduced as challenge animals to Group 4 (between Days 21 and 28) and sheep in Group 10 were introduced as challenge animals to Group 5 (between Days 28 and 35).
  • Cohort A Individual animal bodyweights were determined on Day -8 with sheep ranked by bodyweight from highest to lowest and the 10 animals with the lowest bodyweight removed. The remaining 100 sheep were then sequentially blocked in order of bodyweight (into blocks of 5 animals) and randomly allocated to the 5 treatment groups via the“draw from a hat” method. Allocation was such that each group had a similar group mean bodyweight and range of bodyweights. Group mean bodyweights were compared between groups using One-Way Analysis of Variance within a commercially available software package (Statistix 10.0, Analytical Software 2013) confirming no differences exist at p ⁇ 0.05.
  • Cohort B Individual animal total lice counts were determined on Day 20. The fifty (50) sheep were ranked by lice count (from highest to lowest) then sequentially blocked (into blocks of 5 animals) and randomly allocated to the 5 treatment groups via the“draw from a hat” method. Allocation was such that each group had a similar group mean lice count and range of lice counts within the group. Group mean lice counts were compared between groups using One-Way Analysis of Variance and a commercially available software package (Statistix 10.0, Analytical Software 2013) to confirm no differences exist at p ⁇ 0.05.
  • Group 1 animals were treated 7 days post-shearing.
  • Groups 2 and 3 animals were treated within 4 hours post-shearing.
  • the IVP was applied to the backline using a commercial pour-on applicator fitted with a“T-bar” shower nozzle with the full dose of IVP applied as a single strip from the poll to the tail base.
  • shelf Life Specification The stability studies support a shelf life of 36 months when the product is stored below 30°C (Room Temperature). The specification for the shelf life is provided in Table 20: Table 20. Shelf Life Specification
  • compositions of the invention comprising at least one macrocyclic lactone (e.g. abamectin) and at least one neonicotinoid compound (e.g. imidacloprid) show efficacy against both ectoparasites and endoparasites in a mammal (e.g., Merino sheep).
  • macrocyclic lactone e.g. abamectin
  • neonicotinoid compound e.g. imidacloprid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions topiques pour lutter contre les ectoparasites et les endoparasites chez les animaux, lesquelles comprennent une combinaison d'un agent actif de lactone macrocyclique et d'un agent actif de néomcotinoïde en combinaison avec un véhicule pharmaceutiquement acceptable comprenant un solvant de pyrrolidone et un solvant d'éther glycolique, et facultativement un antioxydant. Cette invention concerne également un procédé amélioré d'éradication et de prévention d'infections et d'infestations dues à des parasites et de lutte contre celles-ci chez un animal, qui consiste à administrer des compositions selon l'invention à l'animal dont l'état nécessite un tel traitement.
PCT/US2020/012450 2019-01-16 2020-01-07 Compositions topiques comprenant un néonicotinoïde et une lactone macrocyclique, procédés et utilisations associés WO2020150032A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2020208145A AU2020208145B2 (en) 2019-01-16 2020-01-07 Topical compositions comprising a neonicotinoid and a macrocyclic lactone, methods and uses thereof
NZ776819A NZ776819A (en) 2019-01-16 2020-01-07 Topical compositions comprising a neonicotinoid and a macrocyclic lactone, methods and uses thereof
AU2023200609A AU2023200609A1 (en) 2019-01-16 2023-02-06 Topical compositions comprising a neonicotinoid and a macrocyclic lactone, methods and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962793301P 2019-01-16 2019-01-16
US62/793,301 2019-01-16

Publications (1)

Publication Number Publication Date
WO2020150032A1 true WO2020150032A1 (fr) 2020-07-23

Family

ID=69423419

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/012450 WO2020150032A1 (fr) 2019-01-16 2020-01-07 Compositions topiques comprenant un néonicotinoïde et une lactone macrocyclique, procédés et utilisations associés

Country Status (3)

Country Link
AU (2) AU2020208145B2 (fr)
NZ (1) NZ776819A (fr)
WO (1) WO2020150032A1 (fr)

Citations (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1390336A (en) 1972-06-08 1975-04-09 Sankyo Co Antibiotic b-41
US3950360A (en) 1972-06-08 1976-04-13 Sankyo Company Limited Antibiotic substances
US4134973A (en) 1977-04-11 1979-01-16 Merck & Co., Inc. Carbohydrate derivatives of milbemycin and processes therefor
EP0002916A2 (fr) 1977-12-19 1979-07-11 Merck & Co. Inc. Dérivé milbemycine ou un mélange de tels dérivés utilisable dans le traitement des infections helmintiques et compositions antihelmintiques contenant de tels dérivés
EP0007812A1 (fr) 1978-08-02 1980-02-06 Merck & Co. Inc. Dérivés carbohydrates des composés C-076, leur préparation et leur emploi comme produits antiparasitaires
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4310519A (en) 1976-04-19 1982-01-12 Merck & Co., Inc. Novel substances and process for their production
US4427663A (en) 1982-03-16 1984-01-24 Merck & Co., Inc. 4"-Keto-and 4"-amino-4"-deoxy avermectin compounds and substituted amino derivatives thereof
US4468390A (en) 1981-02-23 1984-08-28 Sankyo Company, Limited Anthelmintic composition and the use thereof
US4742060A (en) 1985-02-04 1988-05-03 Nihon Tokushu Noyaku Seizo K. K. Heterocyclic compounds
US4855317A (en) 1987-03-06 1989-08-08 Ciba-Geigy Corporation Insecticides and parasiticides
US4859657A (en) 1986-07-02 1989-08-22 Ciba-Geigy Corporation Pesticides
US4871719A (en) 1987-03-24 1989-10-03 Ciba-Geigy Corporation Composition for controlling parasites in productive livestock
US4874749A (en) 1987-07-31 1989-10-17 Merck & Co., Inc. 4"-Deoxy-4-N-methylamino avermectin Bla/Blb
US4963582A (en) 1986-03-25 1990-10-16 Sankyo Company Limited Macrolide compounds, their preparation and their use
US4978677A (en) 1986-03-06 1990-12-18 Ciba-Geigy Corporation C(29)-carbonyloxymilbemycin derivatives for controlling parasitic pets of animals and plants
US5045536A (en) 1986-06-07 1991-09-03 Baker Ivor P Liquid formulations
US5055596A (en) 1987-11-03 1991-10-08 Beecham Group P.L.C. Derivatives of avermectin and milbemycin
US5077308A (en) 1989-02-16 1991-12-31 Merck & Co., Inc. Avermectin ketal derivatives useful as antiparasitic
US5202242A (en) 1991-11-08 1993-04-13 Dowelanco A83543 compounds and processes for production thereof
NZ237086A (en) 1991-02-12 1993-07-27 Ancare Distributors Veterinary anthelminitic drench compositions containing praziquantel and at least one other anthelmintic compound; method of treatment
US5399582A (en) 1993-11-01 1995-03-21 Merck & Co., Inc. Antiparasitic agents
EP0667054A1 (fr) 1992-10-30 1995-08-16 Electric Power Research Institute, Inc Unite de commande d'harmoniques destinee a une unite de traitement de ligne d'alimentation active
EP0677054A1 (fr) 1993-01-18 1995-10-18 Pfizer Inc. Nouveaux agents antiparasitaires apparentes aux milbemycines et aux avermectines
US5496931A (en) 1988-12-19 1996-03-05 Dowelanco Insecticide and miticide A83543 compounds and their method of production by fermentation
US5591606A (en) 1992-11-06 1997-01-07 Dowelanco Process for the production of A83543 compounds with Saccharopolyspora spinosa
US5670486A (en) 1993-03-12 1997-09-23 Dowelanco A83543 compounds and process for production thereof
US5824653A (en) 1994-11-28 1998-10-20 Virbac S.A. Anthelmintic compositions for equidae
EP0892060A2 (fr) 1997-07-18 1999-01-20 Smithkline Beecham Corporation La sous-unité ratA de la Glutamyl-tRNAGln amidotransferase de Chlamydia trachomatis
US5962499A (en) 1995-03-20 1999-10-05 Merck & Co., Inc. Nodulisporic acid derivatives
US6001858A (en) 1994-12-09 1999-12-14 Bayer Aktiengesellschaft Parasiticide formulations suitable for dermal application
US6001981A (en) 1996-06-13 1999-12-14 Dow Agrosciences Llc Synthetic modification of Spinosyn compounds
US6010710A (en) 1996-03-29 2000-01-04 Merial Direct pour-on skin solution for antiparasitic use in cattle and sheep
WO2000074489A1 (fr) 1999-06-04 2000-12-14 Nufarm Limited Compositions biocides stables
US6218407B1 (en) 1995-05-24 2001-04-17 Bayer Aktiengesellschaft Insecticides
US6221894B1 (en) 1995-03-20 2001-04-24 Merck & Co., Inc. Nodulisporic acid derivatives
US6232328B1 (en) 1994-05-20 2001-05-15 Bayer Aktiengesellschaft Non-systemic control of parasites
US6369054B1 (en) 1998-02-23 2002-04-09 Bayer Ag Aqueous agents for combating parasitic insects and acarina in human beings
US6399786B1 (en) 2000-07-14 2002-06-04 Merck & Co., Inc. Nonacyclic nodulisporic acid derivatives
US6426333B1 (en) 1996-09-19 2002-07-30 Merial Spot-on formulations for combating parasites
US6482425B1 (en) 1996-09-19 2002-11-19 Merial Parasiticidal combination
US6489303B2 (en) 2000-10-10 2002-12-03 Wyeth Anthelmintic composition
US20030055089A1 (en) * 1996-12-23 2003-03-20 Kirkor Sirinyan Endoparasiticidal and ectoparasiticidal agents
WO2005085216A1 (fr) 2004-03-05 2005-09-15 Nissan Chemical Industries, Ltd. Composé benzamide substitué par de l’isoxazoline et agent de contrôle d’organisme nocif
US6998131B2 (en) 1996-09-19 2006-02-14 Merial Limited Spot-on formulations for combating parasites
US20060128641A1 (en) 2002-07-19 2006-06-15 Holmes Robert William L Levamisole, avermectins or similar in pyrrolidone solvent
WO2007070606A2 (fr) 2005-12-14 2007-06-21 E. I. Du Pont De Nemours And Company Isoxazolines destinees au controle des invertebres nuisibles
WO2007075459A2 (fr) 2005-12-16 2007-07-05 E. I. Du Pont De Nemours And Company 5-arylisoxazolines pour lutter contre des parasites invertebres
WO2007079162A1 (fr) 2005-12-30 2007-07-12 E. I. Du Pont De Nemours And Company Isoxazolines servant à lutter contre des animaux nuisibles invertébrés
US7262214B2 (en) 2003-02-26 2007-08-28 Merial Limited 1-N-arylpyrazole derivatives in prevention of arthropod-borne and mosquito-borne diseases
US20080039519A1 (en) * 2004-11-09 2008-02-14 Bayer Healthcare Ag Anti-Demodicosis Agent
WO2008122375A2 (fr) 2007-04-10 2008-10-16 Bayer Cropscience Ag Dérivés d'arzlisoxayoline insecticides
WO2009003075A1 (fr) 2007-06-27 2008-12-31 E.I. Du Pont De Nemours And Company Procédé de lutte contre les parasites des animaux
WO2009002809A2 (fr) 2007-06-26 2008-12-31 E. I. Du Pont De Nemours And Company Agents de lutte contre les parasites invertebres
WO2009024541A2 (fr) 2007-08-17 2009-02-26 Intervet International B.V. Compostions d'isoxazoline et leur utilisation en tant qu'antiparasitaires
US7728011B2 (en) 2001-04-09 2010-06-01 Bayer Animal Health Gmbh Dermally applicable liquid formulations for controlling parasitic insects on animals
US8383659B2 (en) 2008-12-19 2013-02-26 Novartis Ag Isoxazoline derivatives as pesticides
US8466115B2 (en) 2011-03-10 2013-06-18 Zoetis Llc Spirocyclic isoxazoline derivatives as antiparasitic agents
US8691256B2 (en) 2008-03-19 2014-04-08 Tyratech, Inc. Pest control compositions and methods
WO2014152980A1 (fr) * 2013-03-14 2014-09-25 Sergeant's Pet Care Products, Inc. Composition antiparasitaire à application localisée ("spot-on") comprenant un néonicotinoïde et un pyréthroïde
US8849259B2 (en) 2008-08-19 2014-09-30 Digimarc Corporation Image processing architectures and methods
US8853186B2 (en) 2011-11-21 2014-10-07 Anacor Pharmaceuticals, Inc. Boron containing small molecules

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2922108A1 (fr) * 2007-10-11 2009-04-17 Virbac Sa Utilisation d'un derive de 1-n-(halo-3-pyridylmethyle)-n-methylamino-1-alkylamino -2- nitroethylene pour la preparation d'une composition pharmaceutique veterinaire pour lutter contre les puces

Patent Citations (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950360A (en) 1972-06-08 1976-04-13 Sankyo Company Limited Antibiotic substances
GB1390336A (en) 1972-06-08 1975-04-09 Sankyo Co Antibiotic b-41
US4310519A (en) 1976-04-19 1982-01-12 Merck & Co., Inc. Novel substances and process for their production
US4134973A (en) 1977-04-11 1979-01-16 Merck & Co., Inc. Carbohydrate derivatives of milbemycin and processes therefor
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
EP0002916A2 (fr) 1977-12-19 1979-07-11 Merck & Co. Inc. Dérivé milbemycine ou un mélange de tels dérivés utilisable dans le traitement des infections helmintiques et compositions antihelmintiques contenant de tels dérivés
EP0007812A1 (fr) 1978-08-02 1980-02-06 Merck & Co. Inc. Dérivés carbohydrates des composés C-076, leur préparation et leur emploi comme produits antiparasitaires
US4468390A (en) 1981-02-23 1984-08-28 Sankyo Company, Limited Anthelmintic composition and the use thereof
US4427663A (en) 1982-03-16 1984-01-24 Merck & Co., Inc. 4"-Keto-and 4"-amino-4"-deoxy avermectin compounds and substituted amino derivatives thereof
US4742060A (en) 1985-02-04 1988-05-03 Nihon Tokushu Noyaku Seizo K. K. Heterocyclic compounds
US4978677A (en) 1986-03-06 1990-12-18 Ciba-Geigy Corporation C(29)-carbonyloxymilbemycin derivatives for controlling parasitic pets of animals and plants
US4963582A (en) 1986-03-25 1990-10-16 Sankyo Company Limited Macrolide compounds, their preparation and their use
US5045536A (en) 1986-06-07 1991-09-03 Baker Ivor P Liquid formulations
US4859657A (en) 1986-07-02 1989-08-22 Ciba-Geigy Corporation Pesticides
US4855317A (en) 1987-03-06 1989-08-08 Ciba-Geigy Corporation Insecticides and parasiticides
US4920148A (en) 1987-03-06 1990-04-24 Ciba-Geigy Corporation Insecticides and parasiticides
US4871719A (en) 1987-03-24 1989-10-03 Ciba-Geigy Corporation Composition for controlling parasites in productive livestock
US4973711A (en) 1987-03-24 1990-11-27 Ciba-Geigy Corporation Composition for controlling parasites in productive livestock
US4874749A (en) 1987-07-31 1989-10-17 Merck & Co., Inc. 4"-Deoxy-4-N-methylamino avermectin Bla/Blb
US5055596A (en) 1987-11-03 1991-10-08 Beecham Group P.L.C. Derivatives of avermectin and milbemycin
US5496931A (en) 1988-12-19 1996-03-05 Dowelanco Insecticide and miticide A83543 compounds and their method of production by fermentation
US5571901A (en) 1988-12-19 1996-11-05 Dowelanco Insecticide and miticide compositions containing A83543 compounds
US5077308A (en) 1989-02-16 1991-12-31 Merck & Co., Inc. Avermectin ketal derivatives useful as antiparasitic
NZ237086A (en) 1991-02-12 1993-07-27 Ancare Distributors Veterinary anthelminitic drench compositions containing praziquantel and at least one other anthelmintic compound; method of treatment
US5202242A (en) 1991-11-08 1993-04-13 Dowelanco A83543 compounds and processes for production thereof
EP0667054A1 (fr) 1992-10-30 1995-08-16 Electric Power Research Institute, Inc Unite de commande d'harmoniques destinee a une unite de traitement de ligne d'alimentation active
US5767253A (en) 1992-11-06 1998-06-16 Dow Agrosciences Llc A83543 Compounds; factors Q, R, S, and T
US5631155A (en) 1992-11-06 1997-05-20 Dowelanco Saccharopolyspora spinosa strain
US5591606A (en) 1992-11-06 1997-01-07 Dowelanco Process for the production of A83543 compounds with Saccharopolyspora spinosa
EP0677054A1 (fr) 1993-01-18 1995-10-18 Pfizer Inc. Nouveaux agents antiparasitaires apparentes aux milbemycines et aux avermectines
US5670486A (en) 1993-03-12 1997-09-23 Dowelanco A83543 compounds and process for production thereof
US5670364A (en) 1993-03-12 1997-09-23 Dowelanco A83543 compounds and process for production thereof
US5840861A (en) 1993-03-12 1998-11-24 Dowelanco A83543 compounds and process for production thereof
US5399582A (en) 1993-11-01 1995-03-21 Merck & Co., Inc. Antiparasitic agents
US6232328B1 (en) 1994-05-20 2001-05-15 Bayer Aktiengesellschaft Non-systemic control of parasites
US5824653A (en) 1994-11-28 1998-10-20 Virbac S.A. Anthelmintic compositions for equidae
US6372765B1 (en) 1994-12-09 2002-04-16 Bayer Aktiengesellschaft Parasiticidal formulations that can be applied dermally
US6001858A (en) 1994-12-09 1999-12-14 Bayer Aktiengesellschaft Parasiticide formulations suitable for dermal application
US5962499A (en) 1995-03-20 1999-10-05 Merck & Co., Inc. Nodulisporic acid derivatives
US6221894B1 (en) 1995-03-20 2001-04-24 Merck & Co., Inc. Nodulisporic acid derivatives
US6444690B2 (en) 1995-05-24 2002-09-03 Bayer Aktiengesellschaft Insecticidal compositions
US6218407B1 (en) 1995-05-24 2001-04-17 Bayer Aktiengesellschaft Insecticides
US6010710A (en) 1996-03-29 2000-01-04 Merial Direct pour-on skin solution for antiparasitic use in cattle and sheep
US6001981A (en) 1996-06-13 1999-12-14 Dow Agrosciences Llc Synthetic modification of Spinosyn compounds
US6998131B2 (en) 1996-09-19 2006-02-14 Merial Limited Spot-on formulations for combating parasites
US6962713B2 (en) 1996-09-19 2005-11-08 Merial Spot-on formulations for combating parasites
US6426333B1 (en) 1996-09-19 2002-07-30 Merial Spot-on formulations for combating parasites
US6482425B1 (en) 1996-09-19 2002-11-19 Merial Parasiticidal combination
US20030055089A1 (en) * 1996-12-23 2003-03-20 Kirkor Sirinyan Endoparasiticidal and ectoparasiticidal agents
EP0892060A2 (fr) 1997-07-18 1999-01-20 Smithkline Beecham Corporation La sous-unité ratA de la Glutamyl-tRNAGln amidotransferase de Chlamydia trachomatis
US6369054B1 (en) 1998-02-23 2002-04-09 Bayer Ag Aqueous agents for combating parasitic insects and acarina in human beings
WO2000074489A1 (fr) 1999-06-04 2000-12-14 Nufarm Limited Compositions biocides stables
US6399786B1 (en) 2000-07-14 2002-06-04 Merck & Co., Inc. Nonacyclic nodulisporic acid derivatives
US6489303B2 (en) 2000-10-10 2002-12-03 Wyeth Anthelmintic composition
US7728011B2 (en) 2001-04-09 2010-06-01 Bayer Animal Health Gmbh Dermally applicable liquid formulations for controlling parasitic insects on animals
US20060128641A1 (en) 2002-07-19 2006-06-15 Holmes Robert William L Levamisole, avermectins or similar in pyrrolidone solvent
US7262214B2 (en) 2003-02-26 2007-08-28 Merial Limited 1-N-arylpyrazole derivatives in prevention of arthropod-borne and mosquito-borne diseases
WO2005085216A1 (fr) 2004-03-05 2005-09-15 Nissan Chemical Industries, Ltd. Composé benzamide substitué par de l’isoxazoline et agent de contrôle d’organisme nocif
US20070066617A1 (en) 2004-03-05 2007-03-22 Nissan Chemical Industries, Ltd. Isoxazoline-substituted benzamide compound and pesticide
US20080039519A1 (en) * 2004-11-09 2008-02-14 Bayer Healthcare Ag Anti-Demodicosis Agent
WO2007070606A2 (fr) 2005-12-14 2007-06-21 E. I. Du Pont De Nemours And Company Isoxazolines destinees au controle des invertebres nuisibles
US20090143410A1 (en) 2005-12-14 2009-06-04 Kanu Maganbhai Patel Isoxazolines for Controlling Invertebrate Pests
US20090133319A1 (en) 2005-12-16 2009-05-28 E. I. Du Pont De Nemours And Company 5-Aryl Isoxazolines for Controlling Invertebrate Pests
WO2007075459A2 (fr) 2005-12-16 2007-07-05 E. I. Du Pont De Nemours And Company 5-arylisoxazolines pour lutter contre des parasites invertebres
WO2007079162A1 (fr) 2005-12-30 2007-07-12 E. I. Du Pont De Nemours And Company Isoxazolines servant à lutter contre des animaux nuisibles invertébrés
WO2008122375A2 (fr) 2007-04-10 2008-10-16 Bayer Cropscience Ag Dérivés d'arzlisoxayoline insecticides
WO2009002809A2 (fr) 2007-06-26 2008-12-31 E. I. Du Pont De Nemours And Company Agents de lutte contre les parasites invertebres
WO2009003075A1 (fr) 2007-06-27 2008-12-31 E.I. Du Pont De Nemours And Company Procédé de lutte contre les parasites des animaux
WO2009024541A2 (fr) 2007-08-17 2009-02-26 Intervet International B.V. Compostions d'isoxazoline et leur utilisation en tant qu'antiparasitaires
US8691256B2 (en) 2008-03-19 2014-04-08 Tyratech, Inc. Pest control compositions and methods
US8849259B2 (en) 2008-08-19 2014-09-30 Digimarc Corporation Image processing architectures and methods
US8383659B2 (en) 2008-12-19 2013-02-26 Novartis Ag Isoxazoline derivatives as pesticides
US8466115B2 (en) 2011-03-10 2013-06-18 Zoetis Llc Spirocyclic isoxazoline derivatives as antiparasitic agents
US8853186B2 (en) 2011-11-21 2014-10-07 Anacor Pharmaceuticals, Inc. Boron containing small molecules
WO2014152980A1 (fr) * 2013-03-14 2014-09-25 Sergeant's Pet Care Products, Inc. Composition antiparasitaire à application localisée ("spot-on") comprenant un néonicotinoïde et un pyréthroïde

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
"Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems", 2005, LIPPINCOTT WILLIAMS & WILKINS
"International Nonproprietary Names for Pharmaceutical Substances (INN", vol. 17, 2003, WHO DRUG INFORMATION, pages: 263 - 286
"Remington Pharmaceutical Sciences", 1986
"The Merck Index", 1996, MERCK & CO., INC.
"The Merck Veterinary Manual", January 2005
ALBERS-SCHONBERG ET AL.: "Avermectins Structure Determination", J. ARTI. CHEM. SOC., vol. 103, 1981, pages 4216 - 4221
DAVIES H.G. ET AL.: "Avermectins and Milbemycins", NAT. PROD. REP., vol. 3, 1986, pages 87 - 121
J VERCRUYSSERS REW: "Macrocyclic Lactones in Antiparasitic Therapy", 2002, CABI PUBLISHING
M.H. FISCHERH. MROZIKWILLIAM C. CAMPBELL: "Ivermectin and Abamectin", 1989, SPRINGER VERLAG
MROZIK H. ET AL.: "Synthesis of Milbemycins from Avermectins", TETRAHEDRON LETT., vol. 24, 1983, pages 5333 - 5336, XP085658302, DOI: 10.1016/S0040-4039(00)87861-2
N. SIMON-DELSO ET AL.: "Systemic insecticides (neonicotinoids and fipronil): trends, uses, mode of action and metabolites", ENVIRON SCI POLLUT RES, vol. 22, 2015, pages 5 - 34, XP035420452, DOI: 10.1007/s11356-014-3470-y
SALGADO V.L.SPARKS T.C.: "The Spinosyns: Chemistry, Biochemistry, Mode of Action, and Resistance", COMPREHENSIVE MOLECULAR INSECT SCIENCE, vol. 6, 2005, pages 137 - 173
SHAO XLIU ZXU XLI ZQIAN X: "Overall status of neonicotinoid insecticides in China: production, application and innovation", J PEST SCI, vol. 38, 2013, pages 1 9
SHAO XSWENSON TLCASIDA JE: "Cycloxaprid insecticide: nicotinic acetylcholine receptor binding site and metabolism", J AGRIC FOOD CHEM, vol. 61, 2013, pages 7883 - 7888
VETERINARY PARASITOLOGY, vol. 49, no. 1, July 1993 (1993-07-01), pages 5 - 15
WATSON GBLOSOMRBABCOCK JMHASLER JMLETHERER TJYOUNG CDZHU YCASIDA JESPARKS TC: "Novel nicotinic action of the sulfoximine insecticide sulfoxaflor", INSECT BIOCHEM MOL BIOL, vol. 41, 2011, pages 432 - 439, XP055032314, DOI: 10.1016/j.ibmb.2011.01.009
WU MCAI JYAO JDAI BLU Y: "Study of imidaclothiz residues in cabbage and soil by HPLC with UVdetection", BULL ENVIRON CONTAM TOXICOL, vol. 84, 2010, pages 289 - 293, XP019797242

Also Published As

Publication number Publication date
AU2020208145B2 (en) 2023-02-02
AU2023200609A1 (en) 2023-03-09
AU2020208145A1 (en) 2021-06-24
NZ776819A (en) 2023-04-28

Similar Documents

Publication Publication Date Title
US20230087923A1 (en) Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof
KR101841302B1 (ko) 다중 활성제를 포함하는 구충제 조성물, 그 방법 및 용도
AU2018205137B2 (en) Long-acting injectable formulations comprising an isoxazoline active agent, methods and uses thereof
AU2015339096B2 (en) Parasiticidal composition comprising fipronil
AU2020208145B2 (en) Topical compositions comprising a neonicotinoid and a macrocyclic lactone, methods and uses thereof
JP6249568B2 (ja) アリールピラゾールと置換イミダゾールを含む組成物、その使用方法
US11583545B2 (en) Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof
AU2015202084B2 (en) Parasiticidal compositions comprising multiple active agents, methods and uses thereof
EP3096739B1 (fr) Formulation à administration topique
NZ710442A (en) Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof
NZ710442B2 (en) Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof
OA16809A (en) Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof.
NZ733600B2 (en) Topical Delivery Formulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20703335

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020208145

Country of ref document: AU

Date of ref document: 20200107

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20703335

Country of ref document: EP

Kind code of ref document: A1